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abstract
Hyperthyroidism is known to impair glucose tolerance, but possible
direct effects of thyroid hormones on the insulin producing b cell of the
islets of Langerhans have not previously been reported. Experiments have been
performed to investigate the interactions between thyroid hormones and rat
pancreatic islets Hn vitro ', using a tissue culture system to maintain the
stability of the extracellular environment. The secondary effects, of hyper¬
thyroidism on pancreatic hormone secretion were thereby excluded.
Thyroxine had no effect on insulin secretion from isolated islets during
one hour incubations. However, after 24 hour tissue culture of islets in the
presence of thyroid.hormones, both insulin biosynthesis and secretion v/ere
significantly reduced in response to higher concentrations of glucose.
Theophylline fully restored insulin release to normal levels. The ultrastructure
and insulin content of islets were not altered by 24 hour exposure to thyroid
hormones, despite a significant inhibition of protein synthesis and a 20%
reduction in total islet protein. Thyroid hormones did not affect the
activity of islet adenylate cyclase.
Thyroid hormones may thus contribute to the glucose intolerance observed
in hyperthyroid states, in part by a direct action on pancreatic B cell meta¬
bolism, and a consequent inhibition of insulin biosynthesis and secretion.
These effects could be a result of a thyroid hormone-induced increase of Na K -
ATPase activity, with the possible effects on intracellular cyclic AMP concen¬
trations, translocation of cations across the plasma membrane and accumulation
of cytosolic calcium.
To overcome the problem of poor islet yield from the pancreas, rats were
pretre3ted with pilocarpine, as described in the Appendix, This significantly
enhanced islet yield, but the islets were unsuitable tor metabolic studies due
to their depleted insulin content. However, long-term islet viability was not




THE HISTORY OF DIABETES MELLITUS
Diabetes mellitus is a disease of modern civilisation.
Nowadays, it is estimated that 10% of American children will develop
diabetes at some time in their lives (Barker, 1977). It is rarely
encountered in primitive societies and epidemological studies have
shown that the advent of urbanisation and technological development
can dramatically increase the prevalence of diabetes, as demonstrated
in the Pacific Islands, the Pima Indians and the South African Bantus
(Marine, 1969; Bennet, 1971; Zimmet, 1977). The English physician,
Thomas Willis (1621-1675) writes: "The Diabetes was a disease so
rare among the Ancients, that many famous physicians made no mention
of it; and Galen knew only two sick of it".
Ancient Descriptions
One of the oldest medical texts, the Papyrus Ebers, dates
approximately at 1500 B.C., mentioned a disease which was probably
diabetes and provides a medical prescription "to drive away the
passing of too much urine" (Papaspyros, 1952). Perhaps the philosophy
of Hippocrates who asserted that no attempt should be made to treat
an incurable disease, and tended to focus on prognosis rather than
diagnosis, made diabetes an unlikely candidate for study by the
Ancient Greek physicians. Certainly it was ignored by the Greeks,
and the disease was not described until the early Christian era.
Little is known about Aretaeus the Cappadocian who may have
been a contemporary of Galen in the second century A.D., and made the
first accurate observations of diabetes. He concluded that the term
"diabetes" was derived from the Greek "to run through a syphon",
and he gave a vivid account of the course of the disease (Fig. 1).
His ideas on the rfile of curative medicine, so divergent from those
of Hippocrates, contain aphorisms which are still pertinent in our
culture; "it is impossible to make all the sick well ... but the
physician can secure respite from pain and intervals in disease and
can render disease latent".
Diabetes is mentioned in the Chinese and Japanese medical
documents of the third century A.D., and Sustrata gives a good account
in the Sanskrit texts of the Ancient Indians (Papaspyros, 1952).
They were the first to recognise that the urine of diabetics was
sweet, preceding European developments by centuries, and they
regarded the disease as a "malady of rich and greedy persons con¬
suming much starchy food".
European Developments
European physicians had little to add to the classical
descriptions of diabetes until Thomas Willis brought a new era of
research to what he named as "the pissing evil", when he confirmed
that the urine of patients with diabetes mellitus was sweet-tasting
and could thus be-distinguished from diabetes insipidus.
Matthew Dobson in 1776 noted that the sweetness was due to the
presence of sugar. The aetiology of diabetes mellitus remained
obscure. Aretaeus thought that it was a disease of the kidneys and
Willis claimed that it was a disorder of the blood, although he
observed that it could be aggravated by psychological factors such
as "sadness and long grief" (Papaspyros, 1952). Thomas Sydenham
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Figure 1
The Extant Works of Aretaeus, the Cappadocian (R.H. Major, 1948).
ON DIABETES
"Diabetes is a wonderful affection, not very frequent among
men, being a melting down of the flesh and limbs into urine. Its
cause is of a cold and humid nature, as in dropsy. The course is
the common one, namely, the kidneys and the bladder; for the
patients never stop making water, but the flow is incessant, as
if from the opening of aqueducts. The nature of the disease then
is chronic, and it takes a long period to form; but the patient is
short-lived, if the constitution of the disease be completely
established; for the melting is rapid, the death speedy. Moreover,
life is disgusting and painful; thirst unquenchable; excessive;
which however, is disproportionate to the large quantity of urine,
for more urine is passed; and one cannot stop them either from
drinking or making water."
(Edited and translated by Francis Adams. London Sydenham
Society, 1856.)
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(1624-1689) attributed the disease to the stomach, while
William Cull en (1710-1790) felt it was due to a disturbance of the
nervous system, Claude Bernard (1813-1878) thought that an
abnormality in the liver led to the disruption of normal nutrition
and hence diabetes. The importance of heredity in the aetiology of
diabetes was demonstrated by Bernard Naunyn (1838-1925), and he also
divided diabetes into three categories, juvenile, senile and organic,
a classification which still stands today in a modified form.
Professor Adolf Kussmaul (1822-1902) who described the classical
air-hunger of diabetic ketosis recognised that diabetes mellitus was
a chemical disturbance and later formulated ideas on the metabolic
acidosis which occurs, but it was not until the late nineteenth
century that the pancreas was implicated as being the cause of
diabetes.
The Pancreas
Some earlier workers did suspect the pancreas. In 1683,
Johan Conrad Brunner showed that the surgical removal of the pancreas
from a dog lead to polydipsia and polyuria, and Sauvages (1706-1767)
mentions that Malphighi had produced diabetes by ligation of the
splenic vein. The proof that the pancreas secretes an essential sub¬
stance came in 1889, when Oscar Minkowski (1858-1931) and
J. Von Mering removed the pancreas from dogs and then observed typical
symptoms of diabetes mellitus in the experimental animals, ending
fatally within a few weeks. They write: "as far as the results of
extirpation of the pancreas are concerned, we have already mentioned
the most important: after complete removal of the organ, the dogs
. 11
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became diabetic. It has not to do simply with a transient
glycosuria, but a genuine lasting diabetes mellitus, which in every
respect corresponds to the most severe form of this disease in man.
The appearance of such diabetes, after complete extirpation of the
pancreas, comes without exception, unless the animals have died from
the immediate effects of the operation".
The first written description of the pancreas dates back to
the fourth century B.C. when it was regarded as a fleshy prop for
the stomach and a support for the aorta. Prior to the discovery by
Mering and Minkowski, Paul Langerhans had produced a doctoral thesis
in 1869 on the structure of the rabbit pancreas, and described
discrete groups of cells or islets which could be differentiated
histologically from the main tissue. These clusters of cells were
named the Islets of Langerhans by E.G. Laguesse in 1893. In the same
year, A.S. Dogiel showed that there was no connection between these
groups of cells and the pancreatic exocrine tissue and Laguesse and
E. Hedon decided that the islets constituted the endocrine portion
of the pancreas. In 1916, Sir Edward Sharpey-Schafer suggested that
the islets secreted a substance controlling carbohydrate metabolism,
and named the hypothetical hormone "insulin" (Papaspyros, 1952).
Treatment of Diabetes and the Discovery of Insulin
Despite the lack of knowledge as to the cause of diabetes
mellitus, it was recognised from very early times that nutrition was
an important element in disease states, and various dietary regimes
have always been imployed in the treatment of diabetes. Even the
Papyrus Ebers (R.H. Major, 1948) contain details of a seven-day
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diet (Fig. 2). Many prescribed diets were based on a reduced
caloric intake, although some physicians claimed that the sugar
lost in the urine should be replaced, and prescribed sweet foods for
their patients! Thomas Willis was the first to use alkalis by
advocating lime water, but his prognosis for diabetes was not
encouraging: "as to what belongs to the Cure, it seems a most hard
thing in this degree to draw propositions for curing". Prior to the
discovery of insulin, a popular remedy was the extracts of Brewer's
yeast. Interestingly, this compound was in later years found to
have an insulin-potentiating effect (E. Glaser and G. Halpbern,1929)
attributable to a dietary agent containing chromium known as the
'glucose tolerance factor' (W. Mertz, 1975).
The period following the great discovery of Mering and
Minkowski, until 1920, was filled with avid attempts to extract the
essential pancreatic substance which would cure diabetes. Various
pancreatic preparations were made, and Zuelzer came close to
success in 1908 when his ethanolic extract of pancreas was given
by intra-venous injection to eight diabetic patients and resulted
in an amelioration of symptoms, but these crude extracts proved to
have such toxic effects, that their continued use was untenable.
Discovery of Insulin
The breakthrough was finally made by two Canadians,
Frederick Banting and Charles Herbert Best, in the summer of 1921,
when they made successful extracts of normal and duct-ligated
canine pancreata that produced a rapid amelioration of diabetes when
given to depancreatectomised dogs. They originally called their
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Figure 2
Papyrus Ebers: "a medicine to drive away the passing of too much
urine".
Prescription:
Cakes Fresh grits 1/8
Wheat grains 1/8 Water 1/3
Green lead earth 1/32
Let stand moist; strain it; take it for 4 days.
Prescription:
Branches of qaded plant 1/4
Grapes 1/8
Sweet beer 1/6
Cook; filter and take for 2 days.
Honey 1/4








Cakes 1/8 Water 1/3
Honey * 1/32
Filter and take 1 day.
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extract 'isletin', but it was later named insulin, as suggested
previously by De Meyer (1909) and Sharpey-Schafer (1916). This
decisive point in the history of diabetes cannot be described without
mention of the Roumanian-born physiologist, N. Paulesco, who in fact,
had also managed to extract insulin a few months before Banting and
Best had even met, and they themselves remained ignorant of
Paulesco's 'Pancreine' in the year of their memorable achivement
(Pavel, 1972).
By the end of 1922, with the aid of J.B. Col lip's isolation
procedure and the chemical engineering skills of the Eli Lilly
Company, insulin became widely available. The use of the crysal-
line form of insulin, obtained by Abel in 1926, reduced the incidence
of local reactions to the available insulins, and ten years later
a new phase in diabetic treatment was prompted by the advent of
protamine (Hagedorn) and protamine zinc (Scott) insulins, since
the incorporation of basic proteins or heavy metals into the insulin
molecule prolong its action.
The relatively small size of the insulin molecule, a factor
which originally gave rise to controversy over its classification as
a protein or polypeptide, made it ideal for research into detailed
molecular structure. Sanger in 1955 (Ryle et al. , 1955) achieved
the first successful elucidation of the amino acid sequence of a
protein using ox insulin. He showed that the intact molecule had
a molecular weight of 6000 and was comprised of a pair of poly¬
peptide chains linked by two disulphide bridges. Later it became
clear that insulins from different species of animals had slight
differences in primary structure (Harris, "1956^ Smith, 1966). In
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1969, Adams et al. described the three-dimensional structure of the
insulin molecule by X-ray analysis of insulin crystals, which exist
in two rhombohedral forms containing a minimum of two or four zinc




The syndrome of diabetes has been sub-divided into at least
five distinct categories, which differ from each other in clinical
features, hereditary and genetic characteristics and probably in
aetiology and pathogenesis. The five groups are:
1. Insulin-dependent (juvenile onset) diabetes mellitus
(IDDM).
2. Non-insulin-dependent (maturity onset) diabetes mellitus
(NIDDM).
3. Maturity-onset type of diabetes in the young, a rare
dominantly inherited mild type of diabetes mellitus
(MODY). (Tattersal1, 1976).
4. Diabetes mellitus or carbohydrate intolerance associated
with certain genetic syndromes (Rimoin, 1976).
5. Secondary diabetes.
Some of the characteristics of insulin-dependent diabetes and
non-insulin-dependent diabetes are summarised in Table I, but most
of the following discussion of aetiology will focus on insulin-
dependent diabetes.
Pancreatic Pathology of Diabetes
The non-specific nature of the macroscopical and microscopical
changes in the diabetic pancreas preclude the characterisation of any
definite pathognomonic features. Autopsies of insulin-dependent
-24-
Table I
SOME CHARACTERISTICS OF INSULIN-DEPENDENT (IDDM) AND NON-INSULIN
DEPENDENT (NIDDM) DIABETES
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diabetics have yielded general information on pancreatic pathology,
but causes of the abnormalities are poorly understood. The main
features of the diabetic pancreas in IDDM are insulitis and a
selective B cell destruction.
Insulitis
Fifty to seventy per cent of insulin-dependent diabetics show a
mononuclear cell islet infiltrate in the first few months from diag¬
nosis, which is not found after one year (Gepts and Pipeleers, 1977).
The B cells are degranulated and pyknotic, with a peri- and intra-
insular infiltration of cells resembling small lymphocytes {Gepts,
1976). These changes have been confirmed by electron microscopic
studies, and may be a manifestation of an autoimmune reaction.
B Cell Destruction
Pancreata from insulin-dependent diabetics have a decreased
number of islets and a reduction in the size of the average islets,
which is secondary to a selective destruction of B cells. Non-insulin
producing cells appear to be preserved (Egeberg, 1976). The number of
B cells in the initial phase of IDDM is 10% or less of the normal, as
illustrated by the nearly negligible basal and post-stimulatory insulin
response in newly diagnosed diabetics (Cerasi and Luft, 1977). Insulin
secretion may resume during periods of remission, but studies
measuring C peptide levels denote a total absence of secretion after
5 years in most, but not all, patients (Steiner, 1977),
The mechanisms of B cell destruction, the causal agents and the
regulation of B cell regeneration are still problematic questions.
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Islets and B cells are probably regenerated throughout life, so that
the total B cell mass represents the balance between B cell renewal
and cell death. Factors governing the growth of the endocrine pancreas
are unidentified, but work on experimental animals indicates that the
rate of replication can be influenced by dietary and hormonal ele¬
ments (Christy, 1977), and that the capacity for regeneration of B
cells has a strong genetic component (Hellerstrom, 1976). Thus IDDM
may become apparent only when regeneration of B cells cannot com¬
pensate for their destruction, and the potential equilibrium of the
system is lost.
The Inheritance of Diabetes
The importance of inheritance in the pathogenesis of diabetes
has been well recognised, but because diabetes is not a single
disease entity, it has been described as the geneticist's 'nightmare',
with little agreement over its exact mode of genetic expression. It
is too common to be dependent on a single gene: diseases acquired
in this way tend to be selected against unless they confer a par¬
ticular biological advantage to the individual» and this has not been
demonstrated for diabetes. Berg (1938) originally noted the "absolute
heredity" of late onset diabetes, and conjugal studies (Tattersall,
1976) have demonstrated a strong genetic component in maturity onset
diabetes (usually non-insulin-dependent). The twin studies of
Tattersall and Pyke (1972) showed that the age of onset of diabetes
was crucial in attempting to understand the characteristics of its
inheritance. All the twin pairs in their survey were concordant for
diabetes if the disease developed after the age of 45, while only 50%
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concordance was found for juvenile onset diabetes, and long-term
follow-up has not revealed any changes in this pattern. This has con¬
firmed the strong genetic predisposition for late onset diabetes,
which differs from the complex and multifactorial inheritance of
juvenile onset diabetes (usually insulin-dependent).
Viral Hypothesis
The onset of IDDM has a seasonal pattern, with an increased
incidence of diabetes occurring in the autumn and winter months (Gamble
and Taylor, 1969). This has led to speculations of an association
between the development of diabetes and the viral infections prevalent
at these times of the year. Localised islet cell damage and a diabetic
state can be produced in mice by infection with the EMC virus
(Craighead, 1968 and 1975; Kromann, 1974), and structural damage to
mouse islets is observed following infection of animals with
Coxsackie B virus (Coleman, 1974). However, the only direct evidence
of viral B cell destruction is the electron-microscopic detection of
perinuclear inclusions of virus-like particles, in the pancreatic duct
cells of both insulin and non-insulin-dependent diabetics (Greider, 1977).
Diabetes and Autoimmunity
Antipancreatic cellular and humoral autoimmunity and concomitant
associations with various HLA antigens are established features of
insulin-dependent diabetes. Preliminary evidence of cell-mediated
immunity against antigens of the endocrine pancreas was gained from the
yin vitro1 leucocyte migration inhibition against human pancreatic
homogenate. The precise nature of the antigen is unknown, but it
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appears to be species and organ specific, and is definitely not
insulin. Whether this eel 1-mediated antipancreatic aggression is
persistent (Irvine, 1976a) or declines over a period of time (Nerup,
1974) is not confirmed.
Autoantibodies against the endocrine pancreas have been detected
using immunofluorescence techniques (Bottazzo, 1974; MacCuish, 1974).
Islet cell antibodies (ICA) are an organ specific class of IgG
(Lendrum, 1976a) elaborated against unidentified cytoplasmic antigens
(Lendrum, 1976a; Bottazzo, 1976). Human ICA cross-reacts with
pancreatic tissue of other species, and also with all types of islet
cells so it is unlikely that humoral autoimmunity is the causative
agent in the selective B cell destruction apparent in IDDM. Elegant
double immunofluorescence experiments with antihormonal antibodies
have clearly shown that ICA is not directed against pancreatic hormones
(Bottazzo, 1976). The prevalence of detectable ICA in the general
population is very low, estimates varying from 0.5% (Irvine, 1976b) to
1.7% (Lendrum, 1976b), compared to one series of newly diagnosed
insulin-dependent diabetics; 85% were ICA positive (Lendrum, 1976a).
This number declines rapidly in the first few months after diagnosis,
indicating that the appearance of ICA is related to the clinical
onset of IDDM.
Persistence of ICA for more than 5 years is associated with
co-existent organ specific autoimmune disease and certain HLA types
(B8, Al, A1+B8, Irvine, 1977). Occasionally, ICA have been detected
several years prior to the development of overt diabetes, in patients
with autoimmune endocrinopathy, in particular idiopathic Addison's
disease (Bottazzo, 1974; Lendrum, 1976a), or first degree relatives of
IDDM patients (Nelson and Pyke, 1976), but the prognostic value and
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clinical significance of ICA remains to be clarified. No correlation
is known to exist between humoral and cellular antipancreatic auto¬
immunity (Christy, 1976).
The human leucocyte antigens (HLA) represent the major human
histocompatibility system, and despite the prevailing lack of insight
into the mechanisms whereby susceptibility to HLA-1inked diseases is
conferred, there are definite associations between IDDM and certain
HLA types of the B and D series (Nerup, 1977). The increased
frequency of IDDM in a group carrying the relevant antigens when com¬
pared to a control group without that particular haplotype (relative
risk) is illustrated in Table II (Svejgaard, 1977; Nerup, 1977).
HLA types B8 and DW3 are shared with several other autoimmune endo-
crinopathies, which suggests a common genetic susceptibility, and
there may be an increase in intra-HLA recombination in families with
more than one juvenile onset diabetic (Rubinstein, 1976).
The above interdependent arguments for a 'nature' or "nurture'
hypothesis of the pathogenesis of IDDM have now been drawn together
into a general theoretical framework. In summary, an unknown
environmental stimulus (possibly of viral origin) triggers off an
autoimmune reaction in predisposed individuals giving rise to B cell
destruction. This susceptibility to the development of IDDM may be
attributable to a certain genetic configuration located in the HLA
region of chromosome 6, which could also influence some of the
features of the disease, and the individual's immune response.
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Table II
RELATIVE RISKS OF IDDM FOR VARIOUS HLA-B AND D PHENOTYPES
(From: Christy, M., Deckert, T. and Nerup, J., 1977).









Data on B-phenotypes compiled by Svejgaard and Ryder (1977).
Data on D-phenotypes compiled by Nerup et al» (1977).




Hyperthyroidism is a disease characterised by an increase in
the total daily output of thyroid hormones, a sustained rate in their
plasma level and an increase in tissue concentrations of these
hormones. The disorder was probably first described by Parry in 1825
(Werner, 1978), who recorded a case of heart failure in a patient who
had a swelling in the thyroid area. Graves (1835) collected three
patients with marked palpitations and swelling of the thyroid; he also
recounted a case in which a woman was incapable of closing her eyes
because her eyeballs were apparently so 'enlarged' and showed "the
white sclerotic ... all around the cornea". Von Basedow (1840)
described the gamut of eye changes and most of the other clinical
features of the disease, but he considered it to be an odd manifes¬
tation of tuberculosis. Rehn (1884), recognising the association
between hyperthyroidism and an enlarged thyroid gland, performed
the first sub-total thyroidectomy for a toxic goitre; elevation of
the basal metabolic rate in hyperthyroidism was originally noted by
Magnus-Levy (1895). A toxic diffuse goitre (Graves Disease) is the
major cause of hyperthyroidism, and with a few rare exceptions,
most other cases are due to a toxic nodular goitre resulting from
the autonomous functioning of a circumscribed area(s) within the
thyroid gland and unrelated to Graves disease (Werner, 1978).
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Thyroid Hormones
Thyroid hormones are derived from thyronine (Fig. 3) by
partial or complete substitution in the 3,5,3' and 5' positions with
iodine atoms. Thyroxine (tetraiodo-L-thyroxine, Ty) and tri-iodo-L-
thyronine (3-5-3' tri-iodo-L-thyronine, T3) are considered to be the
two iodothyronines of physiological importance (Sterling, 1974) and
are illustrated in Fig. 3. Ty was originally isolated by Kendall in
1914 (Kendall, 1929), and circulating iodine was subsequently reported
to be principally incorporated into this hormone (Trevorrow, 1939;
Taurog, 1948). The total concentration of Ty in human serum is
between 3.3 to 6.3 yg/100 ml, of which only 0.03% exists in the free
form (Schussler, 1967; Woeber, 1968) while the rest is bound to three
serum protein carriers. The total concentration of T3 is estimated
to be 0.2 yg/100 ml, of which 0.3% is unbound (Woeber, 1970). Two
thirds of the thyroid hormones are carried by thyroxine-binding
globulin, TBG (Gordon, 1952; Larson, 1952; Sterling, 1964), an acidic
glycoprotein which has the maximal affinity for thyroid hormones of
the three carriers. Thyroxine-binding pre-albumen, TBPA, binds up to
15% of thyroid hormones (Woeber, 1968), but only occurs in humans,
primates and the horse. Serum albumen binds about 10% of thyroid
hormones and has the lowest affinity for them. A rapid exchange
equilibrium exists between Ty, T3, bound thyroid hormones and free
hormones (Thorson, 1969). Only the free form of the thyroid hormones
can enter target tissues and exert their actions at a variety of
intracellular sites. In addition to their more obvious function as a
means of transporting Ty and T3 from the thyroid gland to peripheral















Figure 3 Tyrosine and iodinated thyronines.
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retarding the rate of trans-capillary diffusion, provide a
buffering action to dampen the effects of transient pertubations of
thyroid hormones and act as a reservoir for extra-thyroidal hormone
storage.
The Coexistence of Hyperthyroidism and Diabetes
The earliest record of the relationship between an increase in
thyroid hormone secretion and diabetes mellitus was by Dumontpallier
in 1867. He observed the combination of Basedow's disease (1840)
with diabetes in a young woman, and scattered reports of similar
instances followed, until Sattler in 1909 had collected a series of
56 such cases. In the majority of these, the diabetes appeared after
the onset of hyperthyroidism.
Interest in the coexistence of these two diseases was further
aroused by suggestions that surgical or radiotherapeutic manipulation
of the thyroid gland could be useful in the treatment of diabetes.
A reduction of thyroid function had been noted to improve certain
cases of concomitant diabetes (Falta, 1910; Crile, 1915; Rohdenburg,
1920), but Fitz (1921) concluded that the results of thyroidectorny
on the course of diabetes were not encouraging, and the dangers of
the operation did not warrant its advisability as a diabetic cure.
Allen (1922) rightly pointed out that although glucosuria could be
produced in normal people by overdosage with thyroid preparations, in
addition to the association between diabetes and hyperthyroidism, and
the high carbohydrate tolerance in many cases of myxoedema, it
would be unlikely that the superimposition of two hormone
deficiencies could effect an improvement of health.
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Hyperthyroidism and diabetes nielli tus are both common diseases,
and despite initial controversy, it is now clear that the increased
incidence of diabetes in thyrotoxic patients is more than a coinci¬
dental finding (Lamberg, 1965). Joslin and Lahey (1928) found that
1 % of their 4917 diabetics were hyperthyroid, and Andrus (1932)
reported 3 diabetics in a smaller series of 200 hyperthyroid patients,
but developments in the diagnosis of both diseases have yielded more
reliable data. Regan and Wilder (1940) noted the occurence of
diabetes in 3.2% of 5353 hyperthyroid patients, Foster and Lowrie
(1938) reported 42 patients with hyperthyroidism and diabetes in 1616
diabetics. Andreani (1969) diagnosed a 4.5% incidence of clinical
diabetes in 605 hyperthyroid patients and glucose intolerance has
been observed in up to 57% of patients with hyperthyroidism
(Kreines, 1965). It is interesting that hyperthyroidism due to a
toxic nodular goitre is more likely to be associated with diabetes
than that due to a diffuse toxic goitre (Abt, 1962s Andreani, 1969),
but it may be that the latter group of patients are diagnosed and
treated sooner. Regan and Wilder's study showed that 1.7% of the
exopthalmic group had diabetes, compared to 5.6% of the toxic adenoma
group who were diabetic.
There are at least three possible explanations for the
association between diabetes and hyperthyroidism. Firstly, the com¬
plex physiological changes resulting from an excess of circulating
thyroid hormones may in themselves induce an abnormal carbohydrate
tolerance, through metabolic disturbances and their secondary effects
on pancreatic insulin secretion. It may be that the two diseases
have a common aetiological factor or that certain individuals are
genetically predisposed to both pathologies. Finally, thyroid
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hormones may exert a direct influence on the insulin secretion from
pancreatic B cells.
Effect of Hyperthyroidism on Carbohydrate Tolerance
There is ample evidence that tne development of hyperthyroidism
aggravates an existing carbohydrate disorder (Lakin, 1961) and the
severity of diabetes is generally ameliorated by adequate control of
excess thyroid hormone production (Fitz, 1921; Wilder, 1926; John,
1932; Eller, 1960). The numerous studies of carbohydrate tolerance
in hyperthyroid patients without a previous history of diabetes have
been fraught with inconsistencies, possibly because the patients have
never been properly grouped according to age, sex or the severity
and duration of their thyroid disorders. On the whole, the more
recent surveys agree that a significant proportion of hyperthyroid
patients have a raised fasting blood glucose (Elrich, 1961; Lamberg,
1965; Andersen, 1977). Hyperthyroidism is also associated with oral
glucose tolerance tests of the diabetic type (Hales, 1964; Lamberg,
1965; Doar, 1969) but some authors detected a rapid rise in blood
glucose after an oral glucose load, followed by a steep fall and
normal 2-3 hour blood glucose levels (Goldberg, 1949; Amatuzio, 1954;
Holdsworth, 1968).' This would be consistent with the increased
absorption rate of glucose from the intestine (Althousen, 1938) or
the enhanced gastric emptying rate (Holdsworth, 1968) in hyper¬
thyroidism, both of which make the evaluation of OGTTs difficult.
However, studies attempting to circumvent these problems by using the
IVGTT have emerged with equally conflicting data. In hyperthyroidism,
the glucose disappearance rate, or K value, after an IVGTT has been
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found to be unchanged (Amatuzio, 1954; El rich, 1961; Andreani,
1970), increased (Lamberg, 1965) or decreased (Jacobsen, 1972;
Andersen, 1977).
More detailed measurements of plasma insulin levels during
glucose tolerance tests have also failed to clarify the issue.
Insulin secretion has been found to be normal (Hales, 1964; Klink,
1964), increased (Field, 1966; Doar, 1969; Andersen, 1977), or
decreased (Levy, 1969; Andreani, 1970). However, Holdsworth and
Besser (1968) pointed out that although insulin release in hyperthyroid
subjects may be comparable to that of euthyroid controls, it may be
insufficient in proportion to the blood glucose stimulus.
The metabolic sequelae of hyperthyroidism include an
increase in hepatic gluconeogenesis (Mirsky, 1936; Levine, 1953;
Danowski, 1962), a reduction of hepatic glycogenosis (Cramer, 1913;
Mclver, 1943; Lamberg, 1965), and raised fasting levels of plasma
non-esterified free fatty acids and pyruvate, similar to those
found in diabetes mellitus (Williams, 1943; Hales, 1964; Doar, 1969),
all of which must contribute to the increase in blood glucose. Elgee
(1955) using 1131-1abel1ed insulin detected a more rapid degradation
of the hormone in hyperthyroid subjects, but Genuth (1972) concluded
that the metabolic clearance of insulin was normal. The effects of
circulating catecholamines are enhanced in hyperthyroidism (Porte, 1969;
Brewster, 1956; Woeber, 1966), and they are known to inhibit the
insulin response to glucose (Buse, 1970; Cerasi, 1971). This may
explain some of the abnormalities in carbohydrate tolerance described
above, but there again, catecholamine levels in hyperthyroidism have
been found to be reduced (Stoffer, 1973). Andersen (1977) has also
raised the possibility of peripheral insulin resistance, since
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his hyperthyroid patients had abnormal OGTTs, despite high plasma
insulin levels.
The picture becomes even more confused when patients are
re-examined after treatment, once they are euthyroid. Some authors
claim that the carbohydrate intolerance is reversible. Levy (1970)
reported that 40% of his diabetic patients did not need insulin
after treatment with radioiodine. Others failed to find any improve¬
ment in carbohydrate tolerance following treatment (Cavagnini, 1974;
Kreines, 1965), but again these contradictory results may reflect
poor patient selection and grouping.
Aetiological Association Between Hyperthyroidism and Diabetes
The importance of a genetic influence on susceptibility to
disease has been discussed in relation to diabetes. Organ specific
auto-aggression may be a generalised immune response to an environ¬
mental stimulus in predisposed individuals, which is not necessarily
confined to one particular tissue. Certainly, there are remarkable
similarities in the microscopic appearance of lymphoid infiltration
and endocrine target cell destruction of organs affected by auto¬
immune disease. The prevalence of IDDM in idiopathic Addison's
disease and autoimmune thyroid disorders is 30-50 times that of the
general population (Nerup, 1977), and although the reverse situation
is less clear, there is a higher incidence of non-pancreatic organ
specific autoantibodies in diabetics (MacCuish and Irvine, 1975), in
addition to the 4 to 5-fold increase in the frequency of autoimmune
er.docrinopathy in the diabetic population (Christy, 1977). Never¬
theless, the identity of the putative initiating factor in these
manifestations of immune disease is unknown.
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THE MORPHOLOGY OF PANCREATIC ISLETS
Histology
Diamere (1899) and Shulze (1900) both recognised that the
islets of Langerhans were composed of more than one cell type, and
Lane (1907) submitted the first adequate description of the two
varieties of islet cells on the basis of the selective staining of
their granules. They were called A cells (originally observed by
Ssobolew and Tschassownikow) and B cells. A third category was added
to this classification by Bloom (1931) and Thomas (1937), the C cell.
Gomori (1939) confirmed the existence of A and B cells using
a chrome alum haematoxylin phloxine technique whereby A cells were
identified by red colours and B cells by purple colours, but D cells
also stained red. Ferner developed a silver impregnation technique
specific to A cells (Ferner, 1938) although other workers had diffi¬
culties using this method reliably because of the thick frozen sections
which were necessary (Ferner, 1952).
A modified silver stain was developed by Hellerstrom and
Hellman (1960) and they were able to observe two types of A cells;
Ai with cytoplasmic argyrophyl1ia, and A2 which did not take up
silver. In contradistinction to these findings, the silver
impregnation method of Grimelius (1968) demonstrated mainly the A2
cells, which is perhaps a reflection of the capricious nature of
silver staining, an important factor in the controversy that
surrounded the classification of islet cell types.
The relationship between Ai cells and D cells remained
unresolved for some time. Many authors claimed that A], cells and
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D cells were identical (Lazarus and Shapiro, 1971; Fujita, 1964;
Petersson, 1962), but Conklin (1962) felt that D cells were a pre¬
cursor of B cells, while Like (1967) proposed that D cells were
altered A cells and did not recognise a third cell type. Electron
microscope studies failed to resolve the conflict, with one body
of workers reiterating the synonymity of Ai and D cells (Wellman,
1971) while Deconinck (1971 and 1972) supported the light micro¬
scopic findings of Van Asshe (1970) that D cells consituted a
heterogeneous group of islet cells, which he labelled types III and
IV, in addition to A and B cells.
An agreement on four cell types was eventually established
(Solcia, 1973), and they were to be known as A, B, D and Dls the
latter two corresponding to Deconinek's type III and IV respectively.
D and Dj cells are also found in the gastric mucosa (Fujita, 1974;
Barrington, 1976) as are A cells in some species (Unger and Orci,
1975; Dobbs, 1975; Larsson, 1975). As far as is known, B cells are
exclusive to the pancreas.
Quantitative estimations of islet number, weight and volume
have met with considerable problems because of the heterogeneity of
islet distribution within the pancreas, and of islet size (Gepts,
1957). The human pancreas contains approximately 1 x 106 islets, but
there is a wide variation (Ogilvie, 1937), a higher proportion of
islets residing in the pancreatic tail (Laguesse, 1905). It is
generally believed that the pancreas is composed of 1 to 2% of
endocrine tissue (Laguesse, 1906; De Witt, 1906; Susman, 1942), of
which B cells represent about 80%, A cells 15% and D cells about 5%
(Pictet and Rutter, 1972; Petersson, 1963; Hellman, 1963).
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MacLean and Ogilvie (1955) calculated a mean adult human
islet weight of 1.06 g, of which 0.64 g was B cells and 0.22 g was
A cells. Gepts's calculations were a little higher with a mean islet
weight of 1.36 g (Gepts, 1971). From the developmental viewpoint, a
study by Like and Orci (1972) of 20 human embryos between the ages of
8 to 23 weeks showed that A cells were differentiated by 9 weeks,
followed by the D cells, and B cells appeared at 10.5 weeks.
Function of Islet Cells and Pancreatic Hormones
Insulin synthesis, storage and secretion by B cells has been
extensively studied and will be discussed in more detail later.
Early histological studies provided good evidence that insulin is
stored in the B cell secretory granule (Baron, 1948; Hartcroft,
1955; Logothetopoulos,1964; Lazarus, 1970) and this was confirmed
with the development of fluorescent antibody techniques for the
cellular localisation of hormones (Lacy, 1959; Lazarus, 1970;
Logothetopoulos,1970; Lange, 1975; Erlandson, 1976).
Likewise, it is also well established that glucagon is the
secretory product of the A cells (Logothetopoulos,1960; Volk, 1960;
Baum, 1962). With the categorisation of A cells into two groups
further experimental" evidence conclusively demonstrated that glucagon
resides in the A2 cells. Firstly, protein-bound tryptophan, a
prominent component of the glucagon molecule, is only found in A2
cells (Hellerstrom, 1964). Administration of glucagon to rats and
guinea pigs over a period of time results in degeneration and
involution of A2 cells only (Hellerstrom, 1962; Petersson, 1963) and
histological observations of the uncinate process of the dog pancreas,
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in which no measurable glucagon is present (Benscome, 1955), show
that it is devoid of A2 cells (Hellman, 1962). Definitive proof
came from elegant studies in which Als A2 and B cells were micro-
dissected from sections of equine pancreatic islets and only A2
cells stained for glucagon (Lundquist, 1970).
D cells belong to the APUD classification (Pearse, 1969), as
do A, B and Di cells, and are thought to be of neutoectodermal
origin. Immunochemical localisation of somatostatin to D cells in
several mammals (Pelletier, 1975; Orci, 1975c; Erlandsen, 1976) has
been confirmed by immunofluorescence studies in human and rat islets
(Polak, 1975; Hokfelt, 1975), and ultrastructural localisation of
somatostatin to D cells (Goldsmith, 1975; Refener, 1975). The
belief that gastrin is also a functional product of D cells, at
least in man (Lomsky, 1969; Greider, 1971; Erlandsen, 1976), has
not been firmly established, and is at variance with some studies
(Lofstra, 1974; Tobe, 1974), possibly because of differences in the
type of gastrin antisera used in immunocytochemieal techniques.
The above-mentioned cells are all microscopically identifiable by




The concept of bihormonal metabolic regulation by a single
organ was expressed by Lane (1907) several years before the discovery
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of insulin. He put forward a perceptive theory in his paper on the
histology of the pancreatic islets that "one is led to the con¬
viction that the islets of Langerhans are structures which in all
probability have a function of producing a two-fold substance, which,
when poured into the blood stream, has an important effect on
metabolism".
Banting and Best (1921) themselves observed a rise in blood
sugar immediately after the injection of their crude pancreatic
extract, which persisted for 30 minutes but not surprisingly, their
attention was focussed on the elusive hypoglycaemic 'isletin'.
Aqueous extracts of the pancreas were prepared by Kimball and Murlin
(1923) which also raised blood glucose, and when this glycogenolytic
fraction was isolated in 1929 by Coll ens and Murlin it was called
glucagon, or 'glucose-driving1.
During the early stages of the development of insulin
preparations, glucagon was regarded as an artefact, and it was not
properly evaluated as a discrete hormonal entity until it became
possible to measure circulating glucagon levels by radioimmunoassay
(Unger, 1959; Unger, 1962; Eisentraut, 1968). Pancreatic glucagon
secretion leads to a release of glucose from the liver into the
circulation. Glucagon both increases hepatic glycogenolytic activity
(Sokal, 1964; Rodbell, 1971) and is the most potent gluconeogenetic agent
known (Sokals1966a). Paradoxically, it also stimulates insulin
secretion (Samols, 1965; Crockford, 1966), but although this response
may be part of the entero-insulin axis of hormonal metabolic regu¬
lation or a means whereby basal insulin secretion is maintained during
periods of reduced caloric intake, this aspect of its activity is not
understood.
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Pancreatic glucagon is a straight chain polypeptide with 29
amino acid residues (which appear to have a similar sequence in most
mammals studied so far), and a molecular weight of 3485. Staub
(1953 and 1955) was the first to purify and crystallise glucagon,
and it was synthesised by Wunsch in 1967. Some antibodies raised
to pancreatic glucagon also react with material from the gastro¬
intestinal tract, which has been termed glucagon-like-
immunoreactivity (GLI). The biological significance of this sub¬
stance is still disputable, but the presence of glucagon-1ike
peptides in the gut has been repeatedly observed (Sutherland, 1948;
linger, 1966, 1968; Buchanan, 1967; Polak, 1971). Attempts at
isolation of gut GLI have emphasised the heterogeneity of this
extract (Valverde, 1970; Murphy, 1973; Rosselin, 1974; Conlon, 1975),
which appears to be composed of at least two separate entitites; a
small molecular weight peptide closely resembling pancreatic
glucagon, and a larger species with a molecular weight between 10
and 12 thousand, the effect of which is uncertain (Conlon, 1975;
Gutman, 1973; Gleeson, 1971). Unfortunately, until GLI is more
precisely character!sed, the interpretation of glucagon assays and
hence hypotheses of its physiological function must be approached
with caution.
Somatostatin
Somatostatin, a tetradecapeptide, was originally isolated from
the avian hypothalamus (Vale, 1972; Brazeau, 1973) but has since
been identified in the mammalian gastrointestinal tract, thyroid
gland and pancreas (Hokfelt, 1975). Its presence in the human
pancreas has been confirmed by electron microscope immunohisto-
chemistry (Luft, 1974; Goldsmith, 1975; Rufener, 1975; Dubois, 1975),
and indirect immunofluorescence (Hokfelt, 1975; Orci, 1975c).
Initially an important discovery because of its ability to inhibit
growth hormone secretion from the pituitary, it also inhibits
insulin release in man and in the isolated perfused pancreas of
rat and dog (Alberti, 1973; Gerich, 1974, 1975a, 1975b; Efendic,
1976), and human glucagon secretion (Gerich, 1974; Dobbs, 1975;
Koerker, 1974). A radioimmunoassay for somatostatin has now been
developed (Arimura, 1975; Elde, 1977).
Pancreatic polypeptide
This hormone-like substance containing 36 amino acids
(Chance, 1975), was first found in the avian pancreas (Kimmel, 1971)
M
and later in the pancreas of a variety of animal species including
man (Lin, 1972; Kimmel, 1975). It has now been shown to occur in
a small, rare population of islet cells (Larsson 1975, 1976;
Van Assche, 1976) as well as having a scattered distribution in the
pancreatic exocrine parenchyma and duct epithelium (Larsson, 1975).
It has complex effects on the exocrine pancreas, liver, gall
bladder and gastric mucosa (Lin, 1974a, 1974b; Schwartz, 1976),
but its physiological role is poorly understood.
The Islet as a Unit
The topographical relationship between the different islet
cells has aroused much interest in recent years because of its
possible implications on the functional regulations of pancreatic
endocrine secretion. Indirect immunofluorescence studies with anti-
insulin, anti-glucagon and anti-somatostatin sera have revealed a
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specific distributional pattern of A, B and D cells within islets
(Orci and Unger, 1975; Erlandsen, 1976; Orci, 1977). Several
animal species demonstrate glucagon-containing cells in the
peripheral area of the individual islet, with a sparser, less well
demarcated sub-cortical zone of somatostatin and pancreatic
polypeptide-containing cells, and a mass of B cells at the centre of
the islet, although some A and D cells are also present. A similar
pattern exists in normal human islets except that A and D cells
border the permeating intra-islet vascular channels in addition to
their cortical distribution, as shown diagrammatically in Fig. 4.
This brings into question whether pancreatic endocrine
secretion is governed not only by neural impulses and metabolic con¬
stituents of the extracellular fluid and blood supply surrounding the
islets (these aspects will be discussed later), but also by intra-
islet regulation of hormone secretion through a syncitial network.
The concept is further supported by Orci's finding of gap
junctional complexes (low resistance pathways of inter-cellular
communication) between the adjacent islet cells (Orci, 1975b).
Since glucagon stimulates insulin secretion (Samols, 1965),
and insulin inhibits glucagon secretion (Samols, 1976), while
somatostatin is a powerful suppressor of both insulin (Samols, 1976;
Alberti, 1973; Koerker, 1974; Mortimer, 1974) and glucagon release
(Koerker, 1974; Mortimer, 1974), speculations regarding possible
local feedback circuits have arisen (Unger, 1976; Unger and Orci,
1977; Orci, 1977), but until investigations of the microcirculation
of islet vasculature are complete, such models of intra-islet





Figure 4 Schematic representation of the number and distribution of
insulin, glucagon and somatostatin containing cells in the normal rat
islet (left) and human islet (right). The human islet shows large,
penetrating vascular channels. This pattern divides the total islet
mass into smaller subunits, each of which contains a centre formed
mainly of insulin containing cells arid surrounded by glucagon and
somatostatin containing cells. (From L. Orci in "Insulin and Metabolism"
ed. J.S. Bajaj, Excerpta Medica, 1977, pp.1-10.).
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Unger has suggested that diabetes mellitus is a bihormonal
disorder, implicating glucagon excess as a result of A2 cell
dysfunction in addition to insulin lack (Linger, 1975). Certainly
diabetics show an abnormal glucagon secretion (linger, 1972; Raskin,
1975). Furthermore, Orci and Gepts have noted an increase in the
morphometric density of A2 and D cells in the islets of juvenile
onset diabetics(Orci, 1976; Gepts, 1977). Nevertheless, hyper-
glucagonaemia does not have deleterious effects on glucose
homeostasis if substantial insulin is present (Felig, 1976a) and it
seems that insulin deficiency is the primary pathophysiological
disturbance in diabetes. The role of glucagon in normal subjects
may be to maintain euglycaemia after non-carbohydrate stimulation of
insulin secretion (for example a protein meal) when hypoglycaemia
might otherwise result (Unger, 1969; Felig, 1976b).
B Cell Ultrastructure and Insulin Biosynthesis
The ultrastructural appearance of B cells is similar
throughout the mammalian species. Granular endoplasmic reticulum
and secretory granules are often concentrated on opposite sides of
the cell nucleus, although small ribbons of granular endoplasmic
reticulum may be interspersed among secretory granules. Smooth
endoplasmic reticulum is scarce; polysomes, ribosomes and mito¬
chondria occur throughout the cytoplasm. The Golgi complex is
made up of parallel- arrays of smooth membranes and small vesicles,
usually near the nucleus (Lacy, 1972).
-50-
Insulin Precursors
Preparations of pancreatic slices were originally used to
demonstrate that insulin could be synthesised from radioisotopically
labelled amino acids (Pettinga, 1952; Vaughan, 1954; Light, 1956).
Innovative studies on a human islet cell tumour, consisting almost
entirely of B cells, revealed that labelled amino acids were
initially incorporated into an islet protein of higher molecular
weight than insulin, which was nevertheless strongly bound by
insulin antibodies, and could be cleaved by tryptic digestion to
give insulin (Steiner and Oyer, 1967). Further studies on isolated
rat islets, using pulses of labelled amino acids and cycloheximide,
an inhibitor of protein synthesis, confirmed the hypothesis, that
the synthesis of a larger protein (pro-insulin) precluded the
formation of insulin (Steiner, 1967).
Pro-insulin is a single polypeptide chain, composed of 78
(dog) to 86 (human, horse, rat) amino acid residues (Chance, 1968;
Steiner, 1973). Conversion of pro-insulin to insulin involves the
cleavage of the molecule in two areas, giving rise to insulin and a
connecting peptide (C-peptide) fragment. These events take place
within the secretory granules of the B cell, as will be described
below, so that C-peptide accumulates with insulin in equimolar
amounts, and is secreted with the hormone by exocytosis of the
granule contents (Steiner, 1976a).
There is no definitive evidence of the exact mechanism of
conversion of pro-insulin to insulin. Approximate combinations of
pancreatic trypsin and carboxypeptidase B can convert pro-insulin
to insulin in vitro (Kemmler, 1971), but any disruption of B cells
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by sonication or freezing destroys their converting ability (Steiner,
1974). In an attempt to differentiate between possible converting
enzyme ability or dependence of the process on an intact cellular
environment, crude secretory granule fractions were prepared
(Kemmler, 1970) under conditions of maximal granule stability
(Howell, 1969b). Such granules could convert endogenously labelled
pro-insulin to insulin (Kemmler, 1970), and conversion was effectively
inhibited by granule disruption, suggesting that conversion must
occur within intact secretory granules or closely associated intra¬
cellular organelles. The possible relationship of the pro-insulin
transforming enzymes to exocrine pancreatic proteases has not been
established, but poses an interesting teleological suggestion that
the two groups of enzymes may be co-ordinated during development.
Modern progress in the use of cell-free systems to translate
messenger RNA from rat islets or islet-cell tumours has identified
an insulin precursor larger than pro-insulin (Steiner, 1976b). The
rapidity with which this molecule is transformed to pro-insulin made
it impossible to trace with whole-cell labelling techniques. Now
known as pre-pro-insulin, it consists of pro-insulin with an amino
terminal extension of approximately 2,500 daltons. The postulated
flow of information from the gene for insulin in the chromosomal
DNA to the assembly of the insulin molecule is summarised in Fig. 5.
Insulin Synthesis
Autoradiographs of pulse-chase experiments on B cells, with
tritiated leucine, accompanied by gel chromatographic identification
of the newly-synthesised radio-labelled proteins, have confirmed
<J
Figure 5 (From Steiner, D.F., 1976). Scheme of the molecular biology of
insulin formation. The proinsulin gene is represented in the upper
section. RNA polymerase is necessary for the transcription of messenger-
RNA (mRNA) from the gene, and this then serves to guide the formation of
polypeptide chains on the polyribosomes. The initial translation product,
preproinsulin, is believed to promote the association of ribosomes with
the microsomal membrane, thereby leading to the vectorial discharge of
the peptide chain into the cisternal space of the endoplasmic reticulum.
The N-terminal "pre" region is then rapidly cleaved away from the pro-
insulin in the microsomes (3rd section from top). After folding and
formation of disulfide bonds the proinsulin is transferred to the Golgi
apparatus and converted to insulin and C-peptide which are stored.in
the secretory granules pending release.
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that pro-insulin is manufactured in the rough endoplasmic reticulum
(Howell, 1969a; Orci, 1973). Synthesis of insulin precursors can
be induced by glucose (Steiner and Oyer, 1967) which also stimulates
translation of pro-insulin messenger RNA in short-term experiments
(Permutt and Kipnis, 1972).
The newly-formed proteins are channelled from the rough
endoplasmic reticulum to the Golgi apparatus (Howell, 1969a and
1974; Orci, 1971), by an energy-requiring process (Howell, 1972a)
possibly involving the budding-off of microvesicles (Orci, 1973).
Conversion of pro-insulin is initiated in the Golgi cisternae
(Kemmler, 1970) prior to the formation of mature 3 granules
(Steiner, 1969), and new secretory granules emerge from the Golgi
apparatus to integrate with the pre-existing granule pool. It is not
clear whether new and mature granules mix at random (Sando, 1972 and
1973), accumulate in different cellular compartments (Grodsky, 1970)
or become aligned to intracellular structures such as microtubules
(Orci, 1973). The newly-synthesised proteins packaged in the granule
core mature over the next 45-150 minutes (Howell, 1969a; Orci, 1973),
by continued conversion of pro-insulin to insulin, with granular
accumulation of zinc to form microcrystals of insulin (Kemmler, 1972).
Fig. 6 summarises diagrammatically the time course and series of
events which occur from the production of pro-insulin to the
extrusion of insulin-containing granules by the B cell.
••'I I"-
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THE MECHANISM OF INSULIN SECRETION
The Physiological Control and Modification of Pancreatic Endocrine
Hormones
The maintenance of blood glucose concentrations at appropriate
levels for the adequate nutrition of the central nervous system, by
the endocrine pancreas, implies far more than a simple stimulatory/
inhibitory "feedback" sensitivity to extracellular glucose. Not
only are the fluxes in glucose utilisation during exercise, or
absorption during feeding, rapid and comparatively vast, but at times
of severe stress the actual glucose homeostasis may have to be sub¬
jugated to the requirements of the brain. Thus hypoperfusion of the
central nervous system is accompained by compensatory hyperglycaemia.
Not surprisingly, the apportioning of control to the various factors
which influence islet activity is an unrealistic task when
describing integrated systems of response, but they can be classi¬
fied into four separate groups
1. Central and autonomic nervous system
2. The entero-insular axis
3. Circulating hormones
4. Circulating nutrients and other agents.
The Nervous System
Evidence for central nervous system modulation of islet
hormone secretion arises from experiments where insulin release can
be evoked by behavioural conditioning (Woods, 1972), visual,
olfactory, gustatory or hypnotic stimuli. These responses are
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effected through the parasympathetic innervation of the gut and
pancreas, and can be abolished by atropine (Goldfine, 1970;
Parra-Cavarrubias, 1971). Furthermore, destruction of the ventero-
medial hypothalamus (VMH) in rats results in a chronic increase in
circulating insulin levels, which precedes the B cell hypertrophy
and hyperplasia, and obesity following such lesions (Han, 1970;
Martin, 1974). Stimulation of the VMH increases glucagon secretion
and is accompanied by a reduced insulin release, but the latter is
probably due to the raised adreno-medullary catecholamines
(Frohman, 1971).
The pancreas has both a splanchnic sympathetic innervation and
a parasympathetic vagal supply. The adrenergic and cholinergic
nerve terminals have been identified by light and electron micro¬
scopy, more commonly at the islet periphery. The sympathetic
nervous system also affects insulin secretion through circulating
catecholamines. Adrenaline inhibits glucose induced insulin
release (Malaisse, 1967 ; Karam, 1966), while augmenting glucagon
secretion (Karam, 1966), and noradrenaline has similar effects
(Porte, 1966). There is some evidence for sympathetic regulation
of basal insulin secretion, since a-blocking drugs, such as
phentolamine, increase circulating insulin and glucagon levels
(Robertson, 1973). No consistent alteration in basal insulin
secretion is demonstrable after vagotomy or anti-cholinergic drugs
(Goodner, 1972), and it is probable that parasympathetic innervation
to the pancreas co-ordinates responses to meals, either directly or
through other gastro-intestinal hormones, whereas the sympathetic
supply modulates the autonomic response to stress (Bloom, 1973).
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The Entero-insular Axis
The "entero-insular axis" denotes the multiple neural and
hormonal factors which mediate the insulin response to absorption of
nutrients from the gut. The insulin response to an oral glucose
load is greater than that to intravenous glucose (Mclntyre, 1964;
Elrick, 1964), and it has been estimated that approximately half of
the insulin secreted during glucose ingestion is released under the
influence of gastrointestinal factors, other than the direct effect
of the substrate on B cells (Perley, 1967). It appears that there
are three distinct elements in the control of the endocrine pancreas
during absorption of food. Firstly, there are the nutrients them¬
selves, which provide the main stimulus for islet hormone release.
Secondly, there is accumulating evidence that the various peptides
which have been identified in the gut, such as bombesin, cholecysto-
kinin, enkephalin, gastrin, neurotensin, somatostatin, substance P
and vaso-active intestinal peptide (VIP), act as local neurotrans¬
mitters (Daniel, 1978), and several of these are known to directly
affect insulin secretion (Fig. 7). Finally, it seems likely that
there is an additional endocrine transmitter ("incretin"), which is
released from the gut in response to the absorption of nutrients,
particularly carbohydrates, and which augments insulin secretion in
the presence of glucose. The identity of incretin is not yet
established, but the most favourable gut hormone which could be
identified with such a r61e is gastric inhibitory peptide (GIP)
(Creutzfeldt, 1979).
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Diagrammatic summary of main factors




















Hormones and Other Substances
The hormones which are known to affect insulin secretion are
summarised in Table III, with the exception of thyroid hormones,
which will be discussed in more detail later. The influence of
glucose and other agents on insulin secretion is elaborated below.
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Table III


























































Regulation of Insulin Secretion
Prior to the existence of methods for direct insulin
measurements, the cross-circulation experiments of Gayet and
Guillaumine (1928) had demonstrated that a rise in blood glucose
leads to a release of insulin. Anderson and Long (1947) provided
good evidence that insulin is released in response to hyper-
glycaemia, using an insulin bioassay. The advent of radioimmunoassay
techniques (Yalow and Berson, 1960) finally paved the way for the
detailed qualitative and quantitative studies of insulin release
which have been the focus of modern diabetic research.
Any hypothesis concerning the aetiology of diabetes can only
accrue from a fundamental appreciation of B cell function. Ideally,
only 1in vivo1 observations give a full understanding of the co¬
ordinated chemical, neural and hormonal stimuli which enable the
individual organism to maintain glucose homeostasis. However,
pancreatic islets lend themselves well to 'in vitro' studies.
Transplantation experiments show that a normal blood sugar can be
maintained by denervated islets (Minkowski, 1908; Kemp, 1973) and
the perfused pancreas, pancreatic pieces or isolated islets can be
investigated 'in vitro' with relative ease. Bearing in mind the
limitations of these models, essential information about basic
cellular mechanisms can be gained from such preparations, and they
have been studied extensively to formulate ideas on the regulation
of insulin secretion.
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Factors Influencing Insulin Secretion
(a) Glucose
Glucose is the main physiological stimulus for insulin
secretion. Basal insulin output is modi fed by extracellular glucose
concentrations above 3.5 mmol/1 and the increase in insulin
secretion is proportional to the rise in glucose levels (Coore and
Randle, 1964). The rate curve for glucose induced insulin secretion
is sigmoidal, with a stimulant threshold of 4-6 mmol/1, a large and
rapid stimulation of insulin release over glucose concentrations of
7-10 mmol/1, and a maximal secretion at about 16 mmol/1 (Malaisse,
1967a). One of the main features of insulin secretion is the
rapidity with which the B cell can respond to hyperglycaemia: Portal
venous samples 'in vivo' (Blackard, 1970), and 'in vitro1 prepar¬
ations (Grodsky, 1968a) show that insulin secretion can achieve near
maximal rates within a few seconds to a few minutes of raising the
extracellular glucose concentration. The system demonstrates
saturation kinetics which suggest that the B cell "glucose
recognition unit" is based on enzyme controlled mechanisms (Randle,
1968). Another aspect of insulin release is the marked changes
which occur in time if the glucose stimulation is maintained, in
that the insulin secretory response is biphasic. An abrupt initial
insulin output lasting 5-6 minutes falls as quickly to near basal
values and is followed by a second gradual increase in insulin
secretion which persists while extracellular glucose levels are high
(Grodsky, 1968a). Three explanations have been proposed for this
biphasic pattern:
(1) The existence of intracellular insulin in two distinct
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functional units: a small labile compartment responsible for the
rapid release of insulin, and a larger, more stable compartment,
supplying the former unit and perhaps discharging insulin itself,
although at a slower rate (Grodsky, 1969). This model was further
adapted by suggesting that the smaller compartment consists of
heterogeneous insulin 'packets' with different stimulant threshold
levels (Grodsky, 1972a and 1972b),
(2) The above theory was modified in the light of subsequent
observations of B cell morphology, namely the microtubular skeleton
and the microfilamentous cell web. Possibly the initial secretory
phase results from extrusion by emiocytosis of the B granules in
close relationship to the microfilamentous cell web, while the later
phase corresponds to the mobilisation of secretory granules along
the microtubules (Malaisse, 1974b).
(3) Attractive as the above hypotheses are, they both assume
different dose response kinetics between the two postulated com¬
partments. In fact, the dose response curves of the initial insulin
secretory phase and that of the second phase are remarkably alike,
both achieving saturation at high concentrations of glucose
(Cerasi, 1974), in which case the first and limited response cannot
be explained by the exhaustion of insulin in a small pool or adjacent
to the cell membrane. A different model, which assumes the
generation of three simultaneous events when glucose reaches the B
cell, has been proposed. It is suggested that glucose recognition
encompasses both a positive initiating input with a rapid time course,
and a separate potentiating effect which amplifies the former. The
third input, with an intermediate time course, is a negative feed¬
back inhibition of insulin release (Cerasi, 1975).
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(b) Stimulus recognition
The means whereby the B cell recognises glucose is still
unresolved. There is continuing controversy between the "substrate-
site" hypothesis (Randle, 1968) which suggests that glucose may be
recognised as an insulin secretagogue by its metabolism in the B
cells (Grodsky, 1963; Coore, 1964), and the "regulatory-site"
hypothesis (Randle, 1972), maintaining that the glucose molecule
interacts with a specific receptor on the B cell membrane, and that
this interaction initiates the cellular events leading to insulin
secretion.
(c) The "substrate-site" hypothesis
The following indirect evidence supports the theory that
changes in extracellular glucose concentrations lead to changes in
the rate of metabolism of glucose to a key metabolic intermediate
acting as an intracellular modifier of the rate of insulin
secretion. A diagram of the metabolic pathways of the B cell is
shown in Fig. 8.
(1) Metabolisable sugars such as glucose, mannose and fructose
stimulate insulin release, while non-metabolisable sugars (galactose,
2-deoxyglucose) are poorly active (Grodsky, 1963; Coore, 1964;
Ashcroft, 1973a;Hellman, 1974).
(2) Chemical energy in the form of ATP is a prerequisite for
insulin release. Without energy sources the islet ATP content
declines within 5 minutes, but is maintained by glucose and meta¬
bolisable carbohydrates (Ashcroft, 1973a). Furthermore, inhibitors
of metabolism such as dinitrophenol, oligomycin and antiinycin A also




































Figure 8 Schematic representation of metabolic pathways present in
the pancreatic B ceil. (From: A.E. Lambert, 1975).
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(3) Glucose penetrates rapidly into the B cell (Idahl, 1968;
Matchinsky, 1968) and changes in glycolytic intermediates occur at
least as early as the enhancement of insulin secretion by glucose
(Idahl, 1973; Panten, 1973; Ashcroft, 1973b). Secretion correlates
closely to glucose utilisation, glucose oxidation and islet oxygen
consumption (Hellman, 1974). Reports that rat islet glucose meta¬
bolites do not change with extracellular glucose (Matchinsky, 1972)
have not been confirmed by other workers, but in any event, con¬
centrations of a presumptive insulin releasing metabolite may not
need to show large variations if its rate of flux is the more
important criterion for cellular mechanisms of insulin release.
The nature of the initiating metabolite is still speculative.
The stimulation of insulin secretion by xylitol 'in vivo' (Kuzuya,
1966) and 'in vitro' (Montague, 1967 and 1968) led to the suggestion
that the pentose cycle might provide the signal (Montague, 1969),
particularly as the intra-islet concentration of 6-phosphogluconate
correlated with insulin secretion. However, by far the largest
fraction of glucose is metabolised via the Embden-Meyerhof pathway
(Reese, 1973), and even the small amount of glucose which passes
through the pentose cycle decreases with increasing concentrations
of extracellular glucose (Snyder, 1970; Ashcroft, 1972a).
The action of glyceraldehyde in stimulating insulin release
closely resembles that of glucose (Ashcroft, 1973a; Hellman, 1974d;
Malaisse, 1974a), suggesting that the initiating metabolic signal is
situated at or.below the triose phosphate step of the glycolytic
pathway (Hellman, 1974d), particularly as the stimulant action of
glyceraldehyde is not inhibited by glucosamine or mannoheptulose
(Ashcroft, 1973a; Hellman, 1974d). These two substances inhibit
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isiet glucose utilisation and glucose induced insulin secretion
(Ashcroft, 1972b), probably by blocking glucose phosphorylation, a
step circumvented by glyceraldehyde. Current evidence suggests that
phospho-enol-pyruvate is the most likely glycolytic intermediate
which triggers insulin release, if the "substrate-site" hypothesis
is the correct one. Intracellular concentrations of phospho-enol-
pyruvate (PEP) increase with raised extracellular glucose or
stimulation of the B cell with glyceraldehyde (Sugden, 1977). PEP
can elicit insulin release from B granules incubated with islet mem¬
branes, while other glycolytic intermediates are ineffective (Davis
and Lazarus, 1976), and it is the only product of glycolysis able to
stimulate mouse adenylate cyclase (Capito, 1977). Finally, a rise
in B cell cytosolic calcium is thought to be closely linked to
insulin exocytosis, and observations of non-islet tissue show that
PEP stimulates calcium efflux from isolated liver, heart and islet
mitochondria (Chudapongse, 1973; Sul, 1976; Sugden and Ashcroft, 1978).
(d) The "receptor-site" hypothesis
Although the "substrate-site" hypothesis has survived many
attempts at refutation, the glucoreceptor theory remains a subject
of conjecture. No decisive inferences can be established on the
indirect body of evidence available. The following observations
are pertinent to the possible existence of a "receptor-site" for
glucose.
(1) Certain agents can inhibit insulin release without affecting
glucose metabolism (Cerasi, 1973), but these substances lack
specificity and their effects may be attributable to other com¬
ponents of their action.
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(2) Similarly, cytocholasin B stimulates insulin release while
blocking glucose uptake and metabolism, but again, this effect may
be due to its action on other intracellular events (Lacy, 1973;
Levy, 1974).
(3) Insulin secretagogues can be non-metabolisable, like certain
analogues of arginine and leucine (Fajans, 1974), or do not enter
the B cell, as in the case of sulphonyl ureas (Hellman, 1973).
(4) The a-glucose anomer is a more effective stimulant of insulin
secretion than the 3 anomer (Grodsky, 1974 and 1975), but previously
the 8 anomer was reported to be more rapidly metabolised, since it
caused a greater accumulation of glucose-6-phosphate in islets
(Idahl, 1975). This implied a discrepancy between the more potent
stimulant and cellular metabolism; the stereo-specificity providing
good circumstantial evidence in favour of a glucoreceptor. However,
although 3-D-glucose is taken up more rapidly by the pentose pathway,
phosphoglucose isomerase displays a preferential affinity for a-D-
glucose, and in islets a relative metabolic block occurs in the
handling of 8-D-glucose-6-phosphatase (Malaisse, 1976). Thus the
B cell possesses the same anomeric specificity for glucose metabolism
and insulin release.
(5) The most convincing evidence for a glucose "receptor-site"
comes from experiments using partially purified islet membranes.
This membrane preparation was found to alter its UV absorbance in
response to glucose, mannose and fructose, while non-stimulating
sugars were ineffective (Price, 1973). However, no further
characterisation of the membrane material has been achieved.
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Amino Acids
Amino acids stimulate the release of both insulin and glucagon
(Fajans, 1372; Gerich, 1974a), arginine being the most potent
stimulator in humans, followed by lysine and leucine (Fajans, 1972).
Amino acids evoke a greater glucagon response than an insulinogenic
one, thus providing an effective mechanism for prevention of hypo¬
glycemia following a protein meal, when insulin secretion is also
elicited (Linger, 1969). In vitro, amino-acid-stimulated insulin
release is monophasic in the absence of glucose, but the addition of
even small amounts of glucose (4-5 mmol/1) gives rise to a multi-
it
phasic response (Gerich, 1974a; Pagliara, 1974).
Free Fatty Acids and Ketones
Free fatty acids and ketone bodies do affect insulin (Balasse,
1968 and 1973; Crespin, 1969; Hawkins, 1971) and glucagon (Edwards,
1970; Gerich, 1974b) secretion, but the Hn vivo' response cannot be
typified from the inter-species and inter-experimental variations.
1In vitro1 studies show that short chain fatty acids, long chain
fatty acids and ketones stimulate insulin release in the presence of
non-stimulatory levels of glucose (Hawkins, 1971), and the possible
rQle of these substrates is to ensure sufficient insulin release to
prevent' severe keto-acidosis in starvation (Seyffert, 1967).
Calcium
Calcium is known to link the process of stimulus recognition
to hormone discharge in a wide variety of secretory tissues
(Douglas, 1968). Certainly, the presence of extracellular calcium
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is an essential factor in the initiation of B cell insulin release
by glucose (Hales, 1963a; Malaisse, 1973a), and intracellular calcium
plays a critical role in the regulation of insulin secretion
(Malaisse, 1973a). All insulinotropic agents affect the cellular
movements of calcium, with the exception of those which alter the
intracel1ular response to calcium through systems controlling the
migration and extrusion of secretory granules, such as cytochalasin B
(Malaisse, 1978). Furthermore, the divalent ionophore A23187
stimulates insulin release in the absence of glucose by facilitating
the entry of calcium into the B cell (Malaisse, 1973a). Detailed
studies on isolated islets using labelled ^calcium have shown that
a glucose stimulus induces a rapid accumulation of radiolabelled
calcium from the extracellular medium (Malaisse-Lagae, 1971) and a
concomitant inhibition of calcium efflux from prelabelled cells
(Malaisse, 1973b). This sequence of events is followed by a sharp
rise in calcium efflux coincident with insulin release, although
cationic extrusion does not occur in the absence of extracellular
calcium (Malaisse, 1978). It is not clear whether these movements of
calcium are operated through voltage dependent ionic channels during
depoTarisation of B cells, or by a modification of a native iono-
phoretic system in the cell membrane.
The concentration of cytosolic calcium appears to be the focal
trigger for the insulin secretory mechanism (Hellman, 1975). This is
determined partly by the influx and efflux of calcium across the cell
membrane and also by its uptake and release from intracellular com-
i
partments. X-Ray microanalysis of the calcium distribution in
frozen sections of islet tissue, have shown that B cell mitochondria^
storage granules and other organelles contain significant quantities
of calcium (Howell, 1975a and 1975b), The mitochondrial calcium
pool appears to be the most significant in terms of regulation of
hormonal release (Howell, 1975b). Thus, while potentiators of
insulin release do not alter the cellular uptake of calcium, they
may inhibit the accumulation or increase the efflux from intra¬
cellular organelles to effect a rise in cytosolic calcium concentration
(Montague, 1977). This is unlikely to be a direct effect of secondary
stimuli, since some do not penetrate the B cell, and is probably
mediated by the cyclic AMP system. Glucose stimulation also affects
the movements of other ions in the islet cells; it provokes a sudden
release of inorganic phosphate (Freinkel, 1974), an increased uptake
of potassium (Howell, 1968) and an inhibition of potassium efflux
(Henquin, 1978). However, the significance of these ionic alterations,
or their relationship to the glucose-induced depolarisation of the
B cell membrane (Dean, 1970), is not clear.
Cyclic AMP
Cyclic AMP acts as a "second messenger" in secretory tissues
such as the thyroid and anterior pituitary, and is known to act as
an important intracellular mediator in glucose-induced insulin
release (Montague, 1977). The observation that cyclic AMP potentiated
insulin release in response to glucose originated from the finding that
glucagon was a potent insulinotropic agent, particularly during hyper-
glycaemia (Sharp, 1979). Glucagon acts by stimulating adenylate
cyclase, a membrane-bound enzyme catalysing the formation of cyclic
v>
AMP from ATP (Howell, 1972b), and thus increasing intracellular cyclic
AMP levels. Subsequent studies have noted that substances which effect
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a rise in intracellular cyclic AMP, such as g adrenergic agents,
sulphonyl ureas, phosphodiesterase inhibitors, cholera toxin and
exogenous cyclic AMP enhance glucose-induced insulin release,
particularly at high glucose concentrations (Malaisse, 1967f;
Montague, 1977; Sharp, 1979).
It is unlikely that a direct relationship exists between
glucose, cyclic AMP and insulin release. The rise in intracellular
cyclic AMP provoked by methyl xanthines or cholera toxin is not
associated with a significant enhancement of insulin secretion in
the absence of a primary stimulus such as glucose (Montague, 1977).
After many contradictory observations, it is now generally
agreed that glucose stimulation does increase B cell cyclic AMP
levels (Sharp, 1979) providing extracel1ular calcium is present
(Charles, 1975; Zawalich, 1975). However, theophylline has a far
more pronounced effect on cyclic AMP than glucose, although it is
not accompanied by a. greater insulin release unless glucose is also
present (Charles, 1973). This indicates that cyclic AMP positively
modifies insulin secretion by having a potentiating effect on the
B cell response to a primary stimulus such as glucose.
Adenylate cyclase activity provides an important focus of
control of cyclic AMP levels. Glucose does not appear to directly
affect adenylate cyclase in broken cell preparations (Kuo, 1973;
Howell, 1973a),but its activity can be regulated through a variety
of factors, including long-term substrate availability (Howell,
1973b), and various hormones (Kuo, 1973).
This significance of cyclic AMP in the sequential process which
leads to insulin release appears to be a diverse interaction with
cellular events. Cyclic AMP inhibits the uptake of calcium by
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intracellular organelles (Howell, 1975a), so that it enhances the
rise of cytosolic calcium if calcium efflux is simultaneously
reduced by a glucose stimulus. Another important property of
cyclic AMP is its ability to activate B cell protein kinases
(Montague, 1972) which are functional in the effector system of
hormonal secretion (Rasmussen, 1977; Gillespie, 1975). The means
with which cyclic AMP levels are raised by glucose remain obscured
by the rapid dynamics of the process, but the initial rise in
cytosolic calcium may be instrumental, through activation of
speculative calcium dependent regulator proteins (Sharp, 1979).
These have been demonstrated in other tissues (Rasmussen, 1977), and
may also be implicated in calcium induced extrusion of secretory
organelles (Rasmussen, 1977; Sharp, 1979).
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Discharge of Insulin
In common with all secretory products encased in granular
membranes, insulin is released from the B cell by a process of
exocytosis (Lacy, 1961). Calcium is a universal requisite for exo-
cytosis (Rubin, 1970), which can be defined as the movement of
membrane-bound storage granules to the cell border, fusion of the
granule sac with the plasma membrane and emptying of the granule
contents to the outside of the B cell (Lacy, 1970; Howell, 1971a;
Orci, 1974). The dependency on calcium for insulin release and the
presence of actin and myosin in secretory cells (Abramowitz, 1972;
Blitz, 1974), may reflect the involvement of a contractile system
for granule extrusion (Malaisse, 1973b), since an increase in
cytosolic calcium is essential for exocytosis (Malaisse, 1970; Lacy,
1970). The so-called microtubular-microfilamentous network of B
cells may constitute an active vectorial transport system for the
translocation of B granules to the cell membrane, and their sub¬
sequent extrusion following glucose stimulation (Lacy, 1968;
Malaisse, 1971; Orci, 1972; Lacy, 1975a).
Microtubules are linear, hollow rods composed of tubulin
subunits (Olmsted, 1973; Montague, 1975a) with associated proteins
(Sloboda, 1975), which appear as "fuzzy arms" on the completed micro¬
tubule surface (Dentler, 1975). It has been suggested that the
observed saltatory granule movement towards the plasma membrane
(Lacy, 1975b; Kanazawa, 1976; Malaisse, 1975) is achieved by binding
of granules to the microtubular-associated proteins and directional
orientation of granules along the microtubules to the cell surface
(Ostlund, 1977). This idea is based on the inhibitory effects of
microtubule-disrupting agents, such as colchicine, vinblastine
and vincristine, on insulin release (Lacy, 1968; Malaisse, 1971 and
1972). Unfortunately, these agents act on intracellular systems
other than microtubular structure (Wilson, 1970; Mizel, 1972), which
may also account for their effects. Calcium and cyclic nucleotides
have been implicated in microtubular function (Gillespie, 1975),
but their role is unknown.
Microfilaments are found in B cells as parallel arrays of
lattice networks (Orci, 1972; Malaisse, 1972), and are thought to be
made of actin, which has been identified immunologically in islet
cells (Gabbiani, 1974). They constitute a web near the cell membrane,
extending to surround and connect secretory granules, microtubules
and the plasma membrane (Ostlund, 1977). Disruption of micro¬
filaments by eytochalasin B increases insulin secretion in rat
islets (Lacy, 1973; Van Obberghan, 1973), so it has been proposed
that the microfilamentous cell web normally acts as a barrier to,—
granule release (Orci, 1972), but the effects of cytochalasin B are
not essentially specific to actin-like structures (Sanger, 1972),
and extrapolations from such experiments require more direct
validation.
Present understanding of the microtubular-microfilamentous
network has been incorporated into a theory of intracellular granule
movement and exocytosis of insulin. It is suggested that a glucose
stimulated rise in cytosolic calcium may trigger off the contraction
of microfilaments (Lacy, 1970; Malaisse-Lagae, 1971b), resulting in
extrusion of granules (Ostlund, 1977). Insulin secretion then
continues by movement of granules along microtubules towards the
cell surface. Models of the motive force for granule migration vary
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from microfilamentous contraction (Ostlund, 1977), electrostatic
force (Rebhun, 1972; Kinoshita, 1963) or rapid polymerisation of
microtubules (Murphy, 1974), but so far the evidence for the involve¬
ment of the microtubular-microfilamentous network in insulin
secretion is indirect.
The reverse process of endocytosis has been observed in B
cells. Glucose stimulates an inward flow of vesicles that bud off
from the plasma membrane, allowing membraneous material to be
relocated into the cell concurrently with the addition of granule
sacs to the plasma membrane during exocytosis (Orci, 1973 ).
■>
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THE STUDY OF THE ENDOCRINE PANCREAS "IN VITRO"
Early work on pancreatic endocrine function was based on
estimations of plasma insulin and glucose in response to applied
stimuli in animals and humans. The perfidious nature of this
'in vivo' situation prompted attempts to construct 'in vitro' models
and amplify the details of pancreatic physiology and biochemistry.
Isolation of Endocrine Tissue
Anderson and Long (1947) were the first to isolate the rat
pancreas, perfuse it with synthetic medium and demonstrate that the
organ could be examined under controlled environmental conditions in
the absence of complex neurohumoral influences. Insulin secretion
has also been measured in dogs (Metz, 1960; Seltzer, 1962; Unger,
1967) and rats (Kilo, 1967) by perfusing the pancreas 'in situ' with
its nerve and blood supply intact, a method which was particularly
useful for the investigation of the nervous control of insulin
secretion (Kaneto, 1967; Frohman, 1967). The observation that small
pancreatic pieces could provide viable experimental material
(Bouman, 1960) enabled more systematic and detailed studies to be
done on insulin release (Coore and Randle, 1964b) and synthesis
(Taylor, 1964). The breakdown of insulin and destruction of islet
cells by the proteolytic exocrine enzymes was minimised by addition
of Trasylol (a trypsin inhibitor), so that minced pancreatic tissue
could be used to elaborate on the dynamics of insulin release and
the insulin response to a variety of agents (Burr, 1969a, 1969b,
1971a; Kikuchi, 1974).
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Th e difficult problem for those attempting to study islets,
and one of unknown teleological significance, is that the islets of
Langerhans are embedded in exocrine tissue, and comprise only 1-2%
of the pancreas. Furthermore, the damage often incurred by endo¬
crine cells and hormones from the powerful proteolytic enzymes
released by disrupted acinar tissue precludes accurate estimations
of islet function, and efforts were therefore made to isolate islets
from the surrounding material. Initially, individual islets were
microdissected from pancreata of non-mammalian species such as the
teleost fish (Lazarow and Cooperstein, 1951; Hellman, 1964) or
chickens (Mikami, 1962), but it was not feasible to extrapolate from
these experiments to mammalian systems, since these islets were more
sensitive to amino acids than glucose, as measured by insulin
synthesis (Lazarow, 1964) and secretion (Schirner, 1964). Although
freehand microdissection of mammalian islets was possible
(Hellerstrom 1954), it proved a difficult and tedious task unless
the larger islets of the genetically obese hyperglycaemic mouse were
used (Hellman, 1964). Ingenious microanalytical techniques (Lowry,
1953, 1954, 1957) were applied to B cells microdissected from freeze-
dried pancreatic sections (Lacy, 1962; Smith, 1962; Kissane, 1963)
and have been useful in studying islet cell metabolism (Matschinsky,
1968a, 1971a, 1971b).
Nevertheless, the revolutionary step for this investigative
field was the development of a simple method for the isolation of
intact islets in large numbers, by digestion of the exocrine
elements with collagenase enzymes, which freed the islets from the
acinar cells and allowed them to be collected (Moskalewski, 1965).
Originally tried in guinea pigs, the method was later modified for
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rats and other small mammals (Kostianovsky, 1966; Howell, 1965).
Collagenase digestion has become the most widely-used system for
islet isolation, and the corollary of experiments which followed
its inception has formed the basic understanding of pancreatic
endocrine hormone synthesis and secretion.
However, although the essential separation of exocrine and
endocrine elements has been tackled, a further problem arises in
that the islets are themselves composed of a collection of hetero¬
geneous cells. Efforts have been made to prepare free cell
suspensions by gentle squashing (Petersson, 1966), collagenase
hyaluronidase treatment (Hellman, 1971), tryptic digestion
(Petersson, 1973), application of mild shearing forces (Krause, 1973)
or shaking islets in EDTA (Lernmark, 1974), but islet cells
separated in these ways have not been demonstrably viable despite
being ultrastructurally intact. A tangential solution to these
difficulties has been the use of islets enriched with one or other
cell type, such as the islets from the genetically obese hyper-
glycaemic mouse which contain a raised proportion of B cells
(Hellman, 1964). Alternatively, B cells have been selectively
destroyed by streptozotocin, a B cell cytotoxic agent, leaving islets
composed predominantly of A cells, so that the structure, metabolism
and glucagon release of A. cells could be studied (Howell, 1971b;
Edwards, 1971, 1972). Subcellular fractions such as secretory
granules (Howell, 1969a; Coore, 1969; Lambert, 1970) and plasma mem¬
brane fractions (Price, 1973; Lazarus, 1975; Lernmark, 1976) have
been used to look at intracellular events, but these investigations
are hampered by the lack of sufficient volumes of starting material,
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and difficulties in achieving a satisfactory fractionation of
islet homogenates.
Organ Culture of Endocrine Tissue
Once the techniques outlined above had facilitated a detailed
analysis of the acute events which occur during the biosynthesis,
storage and secretion of insulin and other islet hormones, it was
clearly important to develop methods whereby the endocrine pancreas
could be maintained in organ culture. Such a system is a pre¬
requisite in the investigations of the long-term influences of
environmental situations on islet behaviour, the mechanisms
involved in islet cell regeneration and growth and the accumulation
of sufficient tissue for islet transplantation.
Foetal chick pancreas was cultured by Kappel in 1S26, and
Chen (1954) obtained morphological data of the growth and
differentiation of islet cells in cultures of foetal rat pancreas.
Definitive evidence of the continued growth and development of
islets of such cultures was later established (Schweisthal, 1953;
Clark, 1972; Hegre, 1973), and insulin release from cultured cells
was demonstrated (Wells, 1957; Vecchio, 1967; Lambert, 1970). Orci
(1969, 1970) showed the normal integrity of B cell organelles in
ultrastructural studies of these organ cultures, and the trans¬
plantation of dispersed foetal or neonatal rat pancreas reversed
diabetes in inbred rats both before or after organ culture (Leonard,
1973; Hegre, 1975). An interesting and elegant approach for studying
the induction of differentiation of exocrine and endocrine pancreatic
tissue was the 'in vitro' culture of gut tissue dissected from 10-11
day rat embryos (Spooner, 1970).
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The monolayer culture of cell suspensions of foetal or
neonatal pancreata (Hilwig, 1968; Macchi, 1969; Chick, 1973a) has
been used in basic studies of islet ultrastructure (Orci, 1973a),
hormonal secretion (Lambert, 1972) and B cell replication (Chick,
1973b), despite the difficulties in manipulating such cell sus¬
pensions, or tissue attached to culture dishes. Further problems
arise because foetal and neonatal pancreata are still differentiating
and have a different sensitivity to secretagogues than adult islets,
being more responsive to amino acids than glucose (Milner, 1972;
Grasso, 1973). However, monolayer cultures of a human B cell tumour
have been maintained for 2-7 months with demonstrable insulin
secretory capacity (Chick, 1973c; Yip, 1973; Adcock, 1975), and the
establishment of a functional B cell tumour line would be of great
importance in studies of insulin synthesis and secretion. More
recently, pieces of a human islet cell adenoma were cultured for 7
days without loss of glucose sensitive insulin secretion (Bone, 1977a).
Moskalewski originally established that isolated guinea pig
islets could be "organ cultured" for three weeks with satisfactory
morphological preservation (Moskalewski, 1965, 1969, 1976). The
small size of isolated islets (1-5 ym diameter) reduces the problems
of central tissue necrosis inherent in the culture of larger organs,
and insulin release can still be elicited from B cells in islets
cultured for 6-12 weeks (Andersson, 1967; Westman, 1970;
Kostianovsky, 1972; Andersson, 1972). The cellular composition of
islets remains unchanged (Andersson, 1973) and the glucagon secretory
>
response to arginine (Segerstrom 1976) is still present after culture.
Therefore, despite some changes in B cells during tissue culture, which
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will be elaborated later, this has proved to be a highly successful
method for long-term investigation or storage of islets.
Monolayer cultures of adult islets from guinea pigs, mice and
rats have been obtained (Andersson, 1967; Kostianovsky, 1974), and
used for cinemiorographic studies on the movement of B granules
within the cytoplasm of B cells (Lacy, 1975), but this approach is
limited by fibroblast overgrowth of islet tissue. Artificial
capillary units are proving to be a new and powerful adjunct to
islet cell culture, and have been used to maintain neonatal
pancreatic tissue (Chick, 1975) and adult rat islets (Tze, 1977).
Not only does such a unit mimic the 'in vivo' microvascular system
of cell perfusion and environment, but it also obviates the possi¬
bility of any hormones in the culture medium affecting the B cells.
Culture medium is pumped through the tiny capillaries, and the islets
lie between them; the system shows a surprising lack of fibroblast
proliferation. A reversal of the diabetic state can be achieved in
rats by connecting their vasculature to such a capillary unit con¬
taining isolated islets (Sun, 1976; Tze, 1977).
Effect of Thyroid Hormones on Pancreatic B Cells
The question of direct damage to the endocrine pancreas by
thyroid hormones was investigated by Houssay, in his classic experi¬
ments on dogs (Houssay, 1944 and 1948). He demonstrated that diabetes
could be produced by the administration of thyroid extracts to animals
after sub-total pancreatectomy. The dogs had 4/5 of their pancreata
removed, but were normoglycaemic. When fed thyroid extracts, they
became diabetic (thyroid diabetes) and in some cases permanently so,
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even after cessation of thyroid treatment (metathyroid diabetes).
In both events, the B ceils of the pancreatic remnants showed
histological damage, although the changes were reversible in
thyroid diabetes.
These investigations were not amplified until techniques had
been developed for the study of pancreatic endocrine function 'in
vitro', and the more recent findings will be discussed later.
Attention is currently focussed on the long-term mechanisms for
the control of insulin secretion. Thyroid hormones may directly
influence such a regulatory system, but it is difficult to exclude
the peripheral metabolic effects of hyperthyroidism, which may
themselves evoke changes in insulin secretion. The following work
employs an 'in vitro1 model whereby isolated islets can be main¬
tained viable and functionally intact in tissue culture, so that
it is possible to investigate the interaction between thyroid
hormones and pancreatic islets in a controlled environment.
-84-
CHAPTER 2







































)J Teddington, Middl esex.










' High Wycombe, Bucks.
Pharmacia (GB) Ltd.,
' Ealing, London.
"v Whatman Biochemical Ltd.,
) Maidstone, Kent.
T Glaxo Labs. Ltd.,
' Greenford, Middlesex.
Animals
Ail animals used were female Sprague-Dawley albino rats of a
weight range of 220-250 g. They were maintained on Spratts small
animal diet (no. 1) comprised of 48% carbohydrate, 22% protein and
4.5% fat, and had free access to food and water up to the time of
sacrifice.
Incubation media
The incubation medium used for the following studies was a







MgCl2. 6H20 0.21 1.03
KHzPO^ 0.03 0.22
MgS(V 7H20 0.07 0.28
Na2HP0tf. 2H20 0.113 0.63
CaCl2. 2H20 0.294 2.0
In general, the medium contained 5.5 mmol/1 D-glucose unless
otherwise stated. Any additions made to the medium are described in
the text. The medium was maintained at pH 7.4 by gassing with 95% 02
5% C02 immediately before use, and exposure to atmospheric air was
kept to a minimum.
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Tissue Culture Media
Tissue culture medium 199 with Hanks salts and 0.35 g/1 sodium
bicarbonate (Morgan, 1950) was used for all culture experiments. It
was stored in sterile bottles at +4°C and supplemented with benzyl-
penicillin (100 u/ml) and streptomycin (0.1 mg/ml). The glucose
concentration of the medium was 5.5 mmol/1. New-born calf serum was
added to the medium immediately before use to give a concentration of
5%, under sterile conditions.
Thyroxine
L-Thyroxine was dissolved in 2.5 x 10~3 M-NaOH, and added to the
incubation medium or the tissue culture medium to give a final con¬
centration of 0.1 or 1.0 pg/ml. Media for experimental controls
contained only an identical amount of the dilute NaOH.
Isolation of Islets of Langerhans
The technique used for the isolation of rat islets was
originally described by Moskalewski (1955), and is essentially a
modification of the collagenase digestion procedure (Howell and Taylor,
1966). The animal was sacrificed by cervical dislocation, and the
pancreas with the spleen attached was rapidly removed into chilled
incubation medium. Once the spleen and any excess fat had been
removed from the pancreas, it was distended by subcapsular injection
of medium through a 25 G needle, and finely chopped into small frag¬
ments. The pieces were centrifuged briefly for 2 minutes, and any
remaining fat was drawn off with the supernatant. The tissue was
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transferred with an approximately equal volume of medium into a 25 ml
conical flask and collagenase was adcied. The collagenase consisted
of a mixture of Boehringer and Sigma preparations in equal pro¬
portions; in general, 12 mg of enzyme was used per two pancreata,
although this varied slightly with different batches of collagenase.
The stoppered flask was incubated at 37° C in a rapidly shaking water
bath (200 cycles/min) for approximately 10 minutes. The end-point of
digestion was judged by examination of small aliquots of the tissue,
under a dissecting microscope at lOx magnification.
When sufficiently digested, the tissue was spun down gently in
a bench centrifuge, the supernatant was discarded and the deposit was
washed twice with incubation medium to remove any remaining
collagenase.
Aliquots of this material were transferred into incubation medium
on a plastic petri dish with a black painted base, and examined under
a dissecting microscope. The islets appeared as discrete white
spheres against a translucent background of acinar tissue. The
islets were separated from the exocrine fragments using a finely
drawn out pasteur pipette and collected in a test tube containing
fresh medium.
They were then "re-picked" to allow complete separation from
exocrine elements, and incubated in fresh medium for 30 minutes at
37°C prior to use in an experiment, to allow stabilisation of
insulin release after the isolation procedure. In general, two
pancreata were processed together, and approximately 150-200 islets
could be isolated from each pancreas.
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Insulin Release from Islets During One Hour Batch Incubation
The secretory capacity of isolated islets was assessed using
short-term periods of incubation with various concentrations of
glucose, and measuring the insulin released into the incubation
media after 1 hour. Theophylline, a phosphodiesterase inhibitor
(Butcher, 1962), was also used to stimulate release. Following 30
minutes pre-incubation as described in the islet isolation procedure,
groups of three islets were transferred to flat-bottom tubes con¬
taining 0.6 ml of bicarbonate-buffered medium, pH 7.4 (Gey and Gey,
1936) together with 1 mg/ml albumen, 2, 6 or 20 mmol/1 glucose with or without
5 mmol/1 theophylline. The tubes were gassed with 95% 02, 5% C02,
stoppered, and incubated for one hour at 37°C. At the end of this
period, 100 ul samples of the incubation media were gently withdrawn,
taking care not to remove the islets, and diluted with 900 yl of
phosphate-buffered medium (as described for insulin assay). The
samples were then assayed for insulin. The islets were considered to
be viable if the controls showed a significantly increased insulin
secretion to the high glucose concentration, when compared to basal
levels at 2 mmol/1 glucose, and data was only used from experiments
where this was the case. The mean insulin secretion from islets was
relatively constant for a series of experiments, so that results from




Measurement of insulin throughout this study was by radio¬
immunoassay (Yalow and Berson, 1960; Hales and Randle, 1963). This
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entails the formation of insulin anti-insulin antibody complexes
which can be separated by filtration through glass fibre discs. The
anti-insulin antibody is mixed with the sample to be assayed and a
known amount of radio-iodinated pure insulin. Both labelled and
unlabelled hormones compete equally for antibody binding sites during
a period of incubation, and once equilibrium is reached, the insulin
antibody complex can be separated by filtration and counted for radio¬
activity. Radio-labelled insulin will be present in the filtrate in
inverse proportions to the insulin concentration of the unknown
sample. Thus, the amount of insulin in the sample can be estimated
.
from a standard curve of known concentrations of insulin plotted
against counts of radioactivity in the filtrate.
(b) Reagents
1. Phosphate buffer (50 mM). This was used for dilution of
iodinated insulin, insulin standards and unknown samples, and for
washing the filtrate. It contains, per litre:- ......
Na2HPOtf 5.7 g
NaH^O^ 1.56 g
Bovine Serum Albumen Fraction V 1.0 g
Ethylmercurithiosalicylate 0.25 g
2. Anti-insulin antibody, or insulin binding reagent, is a
freeze-dried stable preparation available commercially. It is raised
against bovine insulin and precipitated with anti-guinea pig globulin.
It has previously been shown not to discriminate significantly between
rat and human insulin over the concentration range 0-4 ng/ml used in
these assays (Montague, 1959a}. Each bottle of binding reagent was
reconstituted with 8 ml distilled water.
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3. Insulin standards were prepared from crystallised human
insulin dissolved in phosphate buffer to give standard solutions of
0.5 to 6.0 ng/ml of insulin. These could be stored at -20° C for
several months without any detectable loss of immunoreactivity. Rat
insulin is comprised of two structurally different molecules (Smith,
1966; Humbel, 1972) which are synthesised in approximately equal
amounts (Steiner, 1967), with a very similar biological activity
(Taylor, 1964). The structural variation is that of different amino
acids at positions 9 and 29 on the B chain where methionine (form II)
is substituted for lysine (form I) (Steiner, 1972) but it is
believed to have little effect on immunological specificity. For
the purpose of this study, it was assumed that the two insulins are
not significantly different in their release characterises or their
immunoreactivity.
4. 125Iodinated ox-insulin was prepared by a modification
(Ewart and Tylor, 1971) of the chloramine T procedure for iodination
of human growth hormone (Hunter and Greenwood, 1962) as described
below.
(c) Preparation of 1251-1abel1ed ox-insulin
Insulin can be iodinated at both tyrosyl and histidinyl
residues, providing that iodine incorporation is kept low to avoid
molecular damage and consequent loss of immunological activity.
The procedure was carried out in a fume cupboard with careful pre¬
cautions against radioactive contamination. 1 mCi of Na 125I in
10 y1 of solution was added to 20 yl of 50 mM phosphate buffer,
albumen free, containing 2.5 yg insulin, in a small assay tube. The
reaction was started by the addition of 20 yl of a freshly prepared
solution of chloramine T (3.5 mg/ml in 50 mM phosphate buffer).
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This was shaken for 10 seconds and the reaction was immediately
stopped by addition of 100 pi of sodium metabisulphite solution
(1.75 mg/ml in 50 mM phosphate buffer), again with shaking. 100 pi
of KI solution (10 mg/ml) and 100 pi of 5% albumen, both in 50 mM
phosphate buffer, were added, and the contents of the reaction tube
were mixed.
[125I]-Insulin was separated from 125I-iodine and [125I]-
proinsulin by gel filtration. The contents of the reaction tube were
fractionated on a Sephadex G-50 column (1 x 50 cm) using 50 mM
phosphate buffer, with albumen, as eluant. 10 pi of each 1 ml
fraction collected were assayed for radioactivity (Fig. 9).
Fractions containing 125I-insulin (peak 2) were pooled, diluted with
eluant buffer to give an activity of approximately 2 x 10s cpm/ml,
and stored at -20°C in small aliquots.
(d) Procedure
100 pi of unknown sample of insulin standard solution was
transferred to bacteriological tubes in triplicate, 100 pi of recon¬
stituted insulin binding reagent was added to each tube, the tubes
were shaken on a whirlimixer and allowed to equilibrate for 4 hours
at 4°C. 125I-Labelled insulin was diluted with 50 mM phosphate
buffer to give approximately 1.5 x 105 cpm/ml, and 100 pi was added
to each tube. After thorough mixing, the tubes were stored at 4°C
for a minimum of 18 hours. Following this second incubation, the
insulin-antibody complex was separated by filtration under vacuum
through glass fibre filters. The tubes and the precipitate were each
washed once with ice-cold phosphate buffer, containing 0.5%
ovalbumen. The filter discs were transferred to plastic tubes and












Figure 9 Gel filtration profile of iodinated insulin. Insulin
(peak 2) was iodinated as described in the text, and separated from
125iodide (peak 3) on a Sephadex G-50 column, using 50 mM phosphate
buffer as eluant. (Courtesy of Dr. K. Pedley).
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standard curve was drawn of ng/ml insulin plotted against radioactivity
in cpm (Fig. 10), and the concentration of insulin in the samples was
then estimated from the graph, as a mean of triplicate observations.
Tissue Culture of Islets
The method of culture of isolated islets of Langerhans was
described by Andersson and Hellerstrom (1972) and the optimal con¬
ditions for islet survival have been further investigated in our
laboratory (Whittaker, 1977).
Islets were isolated and pre-iocubated for 30 minutes in
bicarbonate-buffered medium. Forty to fifty islets were then trans¬
ferred to 5 ml of tissue culture medium 199 (with supplements as
described above) in 5 cm plastic petri dishes. L-Thyroxine was added
to test dishes to achieve a final concentration of 0.1 or 1.0 pg/ml.
Each experiment included a control group of islets in culture medium
to which only dilute NaOH had been added. The islets were then
incubated at 37°C, in a humidified atmosphere of 5% C02:95% air, for
24 hours. Subsequently the islets were again pre-incubated for 30
minutes in bicarbonate-buffered medium prior to their use in experi¬
ments, to wash them free of insulin and serum accumulated in the
culture medium, and also to accustom them to a new medium.
The concentration of thyroxine during tissue culture of islets
was monitored over the 24 hour period. The total thyroxine content
of the samples was determined by immunoassay at the Department of
Biochemistry, Royal Sussex County Hospital, Brighton, Sussex:, the
free thyroxine and free triiodothyronine levels were measured by
equilibrium dialysis by Dr. A. B. Kurtz, Department of Nuclear





Figure 10 Standard solutions of insulin dissolved in 50 mM phosphate
buffer were assayed according to the procedure described in the text.
Each point is the mean of triplicate observations.
Measurement of Radioactivity
125I was counted directly in a Nuclear Chicago Automatic
Gamma System (Model 1195); with a counting efficiency of approxi¬
mately 55%. Tritium was counted in vials in a scintillation solution
of toluene 700 ml: Triton X-100 300 ml: PP0 5 g using a Beckman LS 233
liquid scintillation spectrometer, with a counting efficiency of
approximately 25%.
Expression of Results
Results are expressed throughout as the mean ± the standard
error of the mean (SEM) of the number of observations shown in
parentheses. Differences between means were assessed by the use of
Students ' tJ test or analysis of variance, and were considered





THE DIRECT EFFECT OF THYROID HORMONES ON FRESHLY ISOLATED ISLETS
Introduction
Some hormones directly influence insulin secretion, while others
modify the insulin response to stimuli 'in vivo1 , presumably by an
indirect effect through long-term changes in the islet environment.
Glucagon, corticotropin (ACTH), thyrotropin (TSH) and the prosta¬
glandins have been demonstrated to augment the 'in vitro' insulin
response to glucose from pancreatic pieces or isolated islets in short-
term incubations (Malaisse, 1967b; Johnson, 1973), possibly by acti¬
vating the adenylate cyclase system (Howell, 1973a; Kuo, 1973).
Conversely, somatostatin inhibits insulin secretion from isolated
islets (Efendic, 1975; Claro, 1977), an effect that is more apparent
if islets are exposed to the hormone for longer periods, in tissue
culture (Wollheim, 1977).
The short-term effect of thyroid hormones on the glucose
stimulated insulin release from isolated islets has not previously
been documented. Malaisse and colleagues (1967c) concluded that the
addition of thyroxine to the incubation media did not alter the insulin
secretion from rat pancreatic pieces over 90-minute periods. Never¬
theless, the authors have noted that the enzymes released by the
exocrine elements of pancreatic pieces (Malaisse, 1967d) may lyse both
test hormones and the insulin secreted into the medium (Malaisse, 1967b),
and the acinar tissue will itself metabolise thyroxine. It was there¬
fore important to establish whether any immediate changes in islet
insulin secretion were precipitated by thyroid hormones.
The two prevailing means of investigating insulin secretion by
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iso1ated islets are 'continuous perfusion1 and 'static batch incubation'.
The former method, whereby fresh incubation medium is continuously
pumped over the islets, is technically more exacting, but invaluable
in gauging the post-stimulatory metabolic changes and ionic fluxes
during very short exposures to stimuli, where the immediate dynamic
effects are more pronounced than long-term ones. Static batch incu¬
bation of islets is the simplest and most widely used technique for
measuring insulin release. It has two major drawbacks. Firstly, any
insulin leaking out from dead or damaged cells accumulates in the
static incubation medium together with the secreted insulin, and may
distort eventual conclusions drawn from the experiment; this is of
doubtful significance if small numbers of test islets are used together
with controls. Secondly, the system is insensitive to the multiphasic
nature of insulin release and the inhibitory effects of exogenous
insulin. The negative feedback of insulin on further hormonal
secretion is detectable after approximately one hour of incubation
(Malaisse, 1972). However, where very transient changes are not of
primary importance and incubation periods are limited to 60 minutes,
this particular method provides a simple and readily available
approach, and has been adopted in the following work. The experiments
described in this chapter were set up to investigate the possibility
of a direct short-term effect of thyroid hormones on glucose-stimulated
insulin secretion from isolated islets of euthyroid rats.
Methods
Details of the methods are described in Chapter 2. The islets
were isolated from adult rats by the collagenase procedure and pre-
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incubated for 30 minutes at 37°C. Islets were then batch incubated
in groups of three in bicarbonate-buffered medium containing 2, 6 and
20 mmol/1 glucose with or without theophylline (5 mmol/1), for 60
minutes at 37°C. L-Thyroxine was added to the incubation media of
the test groups prior to incubation, to give a final concentration of
1 pg/ml. All experiments comprised a test group and a control group
at each concentration of glucose. At the end of the one-hour period,
samples of incubation media were withdrawn and assayed for insulin.
Samples could be stored at -20° C for several weeks with no apparent
loss of insulin immunoreactivity.
vjj
Results
The results are shown in Figure 11. Control islets incubated
without thyroxine show a characteristic and significant enhancement
of insulin release with increasing concentrations of glucose. Maxi¬
mal stimulation of insulin release with 20 mmol/1 glucose and
theophylline resulted in a 2.4-fold rise of insulin secretion above
basal levels (at 2 mmol/1 glucose). A similar pattern was also
observed from the islets incubated with thyroxine, with significant
enhancement of secretion at 20 mmol/1 glucose, and a 2.2-fold rise in
basal insulin secretion on maximal stimulation. No significant differ¬
ences were demonstrated between the glucose-stimulated insulin
secretion of control islets and islets incubated with thyroxine.
Discussion
One of the earlier criticisms of the collagenase digestion method
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Figure 11 Direct effect of thyroxine (1 yg/ml) on insulin secretion
from isolated rat islets. Islets were incubated for 60 min at 37°C
in bicarbonate-buffered media containing thyroxine (1 yg/ml), theo¬
phylline (5 mmol/1) and glucose in the concentrations shown. Each
result is the mean insulin secretion in ng insulin/islet/hour ± SEM
of the number of observations shown (n]
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collagenase preparations may damage islets and alter their functional
integrity. The ability of B cells to secrete insulin in response to
changes of secretagogue concentration is probably the most indicative
feature of islet viability. Islets which can modulate their insulin
release must have an intact cell membrane and operative intracellular
organelles. Experiments showing that collagenase isolated islets
exhibit a similar response to agents such as glucose, as islets in rat
or rabbit pancreatic slices (Malaisse, 1967a; Howell, 1967) demonstrate
that collagenase does not adversely affect this parameter of B cell
function. Studies of the ultrastructure of collagenasa isolated islets
show normal cells with no evidence of swollen mitochondria or cell
membrane disruption (Lacy, 1967) and this has been confirmed in our
laboratory (Fig. 12). Comparisons between microdissected and collagen¬
ase prepared islets show close similarities in oxygen consumption
(Hellerstrom, 1968) and glucose metabolism (Montague, 1968; Matchinsky,
1968). Evidently, the collagenase isolation procedure is not del¬
eterious to islet function providing the cells are not overexposed to
the enzymes and the end-point of digestion is carefully assessed.
The results show that the islets were responsive to glucose and
theophylline, and the maximal'levels of insulin secreted compare
favourably with those of other studies (Whittaker, 1977). The islets
treated with thyroxine behaved very similarly. In conclusion, these
experiments confirm the former studies of Malaisse (1967c) on
pancreatic pieces, that there was no immediate effect of thyroid hor¬
mones at the concentrations used on insulin secretion during short-
term periods of exposure to the hormones.
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Figure 12 (x9000 magnification}. Electron micrograph of B cells
from an islet immediately after isolation by the collagenase method,




THE LONG-TERM DIRECT EFFECT OF THYROID HORMONES ON PANCREATIC INSULIN
SECRETION
Introduction
The effects of experimentally produced hyperthyroidism on
subsequent insulin secretion were originally described by Malaisse
(1967c). He noted that in vitro insulin secretion and pancreatic islet
content were reduced by pretreatment of rats with thyroxine, and postu¬
lated a long-term deleterious effect of thyroid hormones on insulin
secretion, possibly through changes in-insulin biosynthesis. Lenzen
and colleagues subsequently persued a variety of these aspects in more
detail, using isolated perfused par.creata from rats with experimental
hyperthyroidism following thyroid hormone administration. In these
preparations, thyroid hormones were found to inhibit the second phase
of insulin release in response to glucose concentrations over 8.3 mmol/1
(Lenzen, 1975; Lenzen, 1978a), although first phase release (which in
fact represents only 1-2% of the insulin secreted over a one-hour period)
was unaffected (Lenzen, 1976a). The reverse situation, using pancreata
from hypothyroid rats following thyroidectomy or propylthiouraci1 treat¬
ment, resulted in an augmentation of glucose induced insulin secretion
above that of normal (Lenzen, 1976b). However, these experiments fail
to discriminate between the possible direct effects of thyroid hormones
on pancreatic B cells and the secondary physiological and metabolic
disturbances of hyperthyroidism, which may damage B cell function.
Modern developments in organ culture techniques for endocrine
pancreatic tissue have created the potential to simulate an in vivo
environment which excludes the effects of the numerous variables arising
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in a living animal. Thus, it is possible to examine the long-term
direct effects of any one factor on pancreatic endocrine secretion
whilst maintaining the stability of cellular surroundings. Careful
observations of B cells in tissue culture have established that they
retain the qualitative features which characterise their viability,
so that such in vitro models can be compared to in vivo conditions.
Andersson has elaborated on Moskalewski1s findings of good
morphological preservation of guinea pig islets maintained in tissue
culture for three weeks (Moskalewski, 1965, 1969 and 1970), with
microscopical details of mouse islets. The islets were histologically
normal after twelve days in tissue culture. There was no evidence of
necrotic areas, and the islets merely showed a diminution of capillary
spaces and a lack of contaminating fibroblasts (Andersson, 1972).
Electron micrographs confirmed the absence of structural derangements
in A2 or B cells (Andersson, 1974 ), and the cellular composition of
the islets was unchanged (Andersson, 1973a). The continuing production
of insulin has been shown in cultured rabbit islets (Boder, 1969) and
monolayer cultures of B ceils, several weeks after explantation
(Andersson, 1970), with retention of the regulatory mechanisms of insulin
release (Lambert, 1971). Measurements of basal rates of islet oxygen
consumption and glucose oxidation were higher in cultured islets, but
showed a similar increase in response to a raised extracel1ular glucose
as did freshly isolated islets (Andersson, 1972). Mitoses were
observed in islets in tissue culture (Andersson, 1973b) and DNA synthesis
can be demonstrated with the addition of H3-thymidine to the culture
medium (Andersson, 1975), Other aspects of islet function and meta¬
bolism which retained similar character!tics in tissue culture were
adenylate cyclase activity (Howell, 1973b), the levels of ATP and
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glycogen, and the activity of the glucose phosphokinases
(Andersson, 1974b).
The major changes which occur during tissue culture are a
reduction of islet insulin content (Andersson, 1972; Ziegler, 1974),
and a quantitative decrease in insulin secretion and biosynthesis,
particularly in response to raised concentrations of glucose
(Andersson, 1974 ). This co-incides with a relative degranulation of
B cells during culture (Moskalewski, 1965, 1969; Westman, 1970;
Andersson, 1972), although A2 cells are little, if at all, affected
(Andersson, 1974 ; Moskalewski, 1976). Nevertheless, mouse islets
cultured for 8 months have remained functional (Andersson, 1978), as
have human islets, which still retain a biphasic insulin release to
an acute glucose load after several months of tissue culture
(Andersson, 1977).
Isolated islets from euthyroid animals were used in the
following experiments in a tissue culture system, to explore any long-
term direct effects of thyroid hormones on glucose stimulated insulin
secretion.
Methods
The details of the methods are described in Chapter 2, The
islets were isolated from normal adult rats. Following a 30 minute
pre-incubation period, groups of 40-50 islets were transferred to
petri dishes containing tissue culture medium (t.c.m.) 199, L-Thyroxin
0..1 or 1.0 yg/ml was added to the test dishes, each experiment
including a control group of islets in hormone-free medium, and the
islets were cultured for 24 hours. Subsequently the islets were again
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pre-incubated for 30 minutes in bicarbonate-buffered medium prior to
their use in the experiments. Glucose stimulated insulin secretion
was then determined by batch incubation of islets as previously
described. After one hour, samples of incubation media were with¬
drawn and immunoassayed for insulin. It should be noted that
thyroxine was not added to the incubation media during these secretion
tests performed after a period of culture.
The concentration of thyroxine during tissue culture of islets
was monitored over the 24-hour period. 0.5 ml of culture media were
taken at 0, 20 and 24 hours and assayed for total thyroxine content
and free thyroxine levels, by immunoassay and equilibrium dialysis
respectively.
Results
Islets were cultured for 24 hours with thyroxine and their
subsequent insulin secretory response to 2, 6 or 20 mmol/1 glucose
with or without theophylline is shown in Fig. 13 and 14, Both
groups of control islets were generally less responsive to glucose
than freshly isolated islets.. In addition there was some variability
between the control values of insulin secretion shown in Fig. 13
and those in Fig. 14, although the islets had undergone the same
experimental procedure. The exact reasons for this are not known,
but it may reflect the influence of different batches of collagenase
(Toiedo-Pereyra, 1979) and calf serum on the secretory response of
islets after tissue culture (Whittaker, 1977). For this reason,
each experiment was always accompanied by a control group of islets
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Figure 13 Insulin secretion from isolated islets cultured for 24 hours
with 0.1 yg/ml thyroxine. Islets were transferred from the culture
media and incubated for 60 minutes at 37°C in bicarbonate-buffered
media containing theophylline (5 mmol/l) and glucose in the concentrations
shown, but no thyroxine. Each result is the mean insulin secretion in
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Figure 14 Insulin secretion from isolated islets cultured for 24 hours
with 1.0 yg/ml thyroxine. Islets were transferred from the culture
media and incubated for 60 minutes at 37°C in bicarbonate-buffered
media containing theophylline (5 mmol/l) and glucose in the concentrations
shown, but no thyroxine. Each result is the mean insulin secretion in
ng insulin/islet/hour + SEM of the number of observations shown (n).
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Fig. 14 shows that the islets cultured with 1.0 yg/ml
thyroxine did not respond to an increase in glucose concentration
from 2-20 mmol/1, and this inhibition of insulin release was highly
significant compared to cultured control islets (p < 0.01). The
addition of theophylline to the incubation media during tests of
secretory capacity restored the insulin response of thyroxine treated
islets to normal levels. Thus, at high glucose concentrations with
theophylline there was no significant difference between the insulin
release from control islets, or those treated with thyroxine (1 yg/ml).
The increase in insulin secretion that was elicited by the
& ■
.
addition of theophylline to 20 mmol/1 glucose media was 0.45±0.28 ng
insulin/islet/hour for control islets, and 1.51±0.34 ng insulin/
islet/hour for the thyroxine treated islets. The enhancement of
insulin release by theophylline was, therefore, significantly higher
in the thyroxine (1 yg/ml) treated group (p < 0.001).
Thyroxine concentration in the culture media
The total thyroxine in the culture media for experiments using
an estimated concentration of 1.0 yg/ml was as follows:
At the start of the culture period 0.95±0.15 yg/ml (n = 3), at
20 h 0.81±0.15 yg/ml (n = 3), at 24 h 0.79±0.12 yg/ml (n = 3).
Approximately 99% of the thyroxine in the culture media v/as bound to
the plasma protein fraction of the added new-born calf serum. The
free thyroxine concentration was 14.4 ng/ml at the start of the
culture period, and 9.5 ng/ml at the end of culture. Analyses of the
free hormone levels in the media revealed that tri-iodothyronine was
present in small quantities in the thyroxine preparation: The value
-113-
being 0.15 ng/ml of tri-iodothyronine at the start of incubation,
and 0.13 ng/ml after 24 hours.
Piscussion
It has been established that the 'free floating1 culture system
used here, where islets do not become adherent to the bottom of the
dish, is the most suitable for islet incubations (Andersson, 1978).
Extrapolations from data of rates of glucose oxidation by islets in
culture show that the islet tissue has a negligible influence on
substrate and metabolite levels of the culture medium during incu¬
bations of up to four days (Andersson, 1972), Therefore, it can be
assumed that the thyroxine treated islets were maintained at a physio¬
logical glucose concentration throughout the 24-hour period. There
was no gross degradation of thyroxine in this time, as two thirds of
the free Ti+ was still present after 24 hours. Approximately 1% of
the free hormone in the media was tri-iodothyronine, and the results
therefore relect the effects of a combination of T^ and T3,
One consistent aspect of tissue culture of islets which is
still poorly understood is the diminution of glucose sensitivity and
a decreased capacity to secrete insulin after a period of culture
(Andersson, 1972; Rabinovitch, 1978). The addition of a phospho¬
diesterase inhibitor such as theophylline (Butcher, 1952) or iso-
butylmethylxanthine (IBMX) to the incubation media during subsequent
secretion tests can restore the glucose induced insulin secretion to
more normal levels (Andersson, 1972; Rabinovitch, 1978), which
implies that tissue culture may involve changes in the islet cyclic




unaltered during culture at 5.5 mmol/1 glucose (Howell, 1973b;
Whittaker, 1977), as is the basalcAMP content (Rabinovitch, 1978).
Interestingly, the rise in cyclic AM? that accompanies glucose
stimulated insulin release in freshly isolated islets (Gerich, 1976)
was not detected in islets after tissue culture (Rabinovitch, 1978).
The normalisation of the glucose induced insulin response by phospho¬
diesterase inhibitors suggests that the effector mechanisms for insulin
release are unaltered by tissue culture and continue to be responsive
to the postulated signal derived from cyclic AMP. It appears that an
increase in cyclic AMP is not a prerequisite for insulin secretion to
take place, but it may be essential for the establishment of a normal
response to glucose, and the initiatory events including the cyclic
AMP system on exposure to glucose may be altered by tissue culture.
Whether the changes take place at the B cell membrane or reflect, a
metabolic deficiency is still conjectural. The presence of serum during
culture at 5,5 mmol/1 glucose is an acknowledged necessity for islet
survival (Andersson, 1978); possibly it contains essential chemical
factors which are not included in TCM 199. Unfortunately, culture
with different batches of sera results in variations of islet function
(Whittaker* 1977) as was seen in the control groups of islets indicating
that the sera are not standardised for these unidentifed requirements.
In the experiments in this chapter, the glucose induced insulin
secretion by control islets after tissue culture was less than one
half that of freshly isolated islets (Chapter 3). Nevertheless, despite
a diminished sensitivity, the control groups were evidently viable after
24 hours, since high concentrations of glucose and the inclusion of
theophylline could elicit a significant increase in. insulin secretion.
In the case of thyroxine treated islets, insulin secretion in response
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to 2 and 6 mmol/1 glucose was not affected by culture with thyroxine,
and was comparable to the control values. However, thyroid hormones
inhibited insulin secretion at 20 mmol/1 glucose, and this pattern
closely parallels observations of a reduced secretory response to
glucose by the perfused pancreas isolated from thyroxine treated rats
(Lenzen, 1976b). In these dose-response experiments, an inverse
correlation was found between the thyroid status of the animals and the
subsequent pancreatic insulin secretion. When theophylline was added
to the incubation media, the insulin release of thyroxine (1 pg/ml)
treated islets was restored to normal control levels, indicating that
the secretory capacity of the B cells was still intact. This reversal
of the inhibitory action of thyroid hormones suggests that they have a
specific effect on the regulation of insulin secretion in response to
glucose which can be reversed by a phosphodiesterase inhibitor, rather
than acting as a general toxic factor.
There are some striking similarities between the inhibition of
insulin secretion seen in. starvation and that reported here as a result
of thyroxine treatment at normal and constant glucose concentrations.
An impairment of glucose stimulated insulin secretion as a result of
fasting is evident in vivo (Grey, 1970), in pancreatic pieces from
starved animals (Malaisse, 1967e) and in tissue culture experiments in
which islets are maintained in low glucose concentrations (Andersson,
1976a). The latter experiment indicates that these alterations in
islet function are a direct result of prolonged hypoglycaemia, rather
than the other complex metabolic changes that occur during fasting.
Studies on B cell function from pancreata of hyperthyroid or starved
animals show that the defective insulin secretion can be normalised
by intermediates of glycolysis in both cases (Lenzen, 1975, 1976a;
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Levy, 1976). Furthermore, the pattern of enhancement of insulin
secretion by theophylline is similar in islets from starved animals
(Levy, 1976) and the thyroxine treated islets described here.
The alterations of insulin secretion during starvation imply
the existence of long-term mechanisms of control and regulation,
possibly through changes in glucose metabolism (Levy, 1976) or the
cyclic AMP system (Howell, 1973b). These will be discussed in more
detail later, but it appears that thyroid hormones influence these




THE EFFECT OF THYROID HORMONES ON THE INSULIN AND PROTEIN CONTENT,
AND ULTRASTRUCTURAL APPEARANCE OF PANCREATIC ISLETS
Introduction
It seemed possible that any depletion of B cell insulin stores
might play a r61e in the alteration of glucose induced insulin
secretion by thyroid hormones. Therefore the insulin and protein
content of isolated islets cultured for 24 hours in the presence of
thyroxine (1 yg/ml) was investigated. Studies were also made of the
ultrastructural appearance of thyroxine treated islets to detect any
intracellular derangement.
Methods
Isolated islets from euthyroid animals were cultured for 24
hours with 1.0 yg/ml thyroxine as previously described. At the end
of the culture period, they were washed three times in bicarbonate-
buffered medium, and a few islets were collected after the washing
procedure for electron microscopic studies. The protein and insulin
content of the remaining islets was then estimated..
Groups of ten islets were homogenised in a glass tissue
homogeniser with 0.2 ml ethanol:HC1:water (23.5:0.45:7.0) and 0.2 ml
water. Samples of the homogenate were taken for protein estimation by
the method of Lowry (1951) using crystalline albumen standards, and
insulin content by immunoassay after dilution with 50 mM phosphate
buffer.
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Measurement of Islet Protein Content
Principle
The method is based on Lowry's (1951) calorimetric reaction
between the tryptophan and tyrosine residues of the protein in
alkaline copper solution and phosphomolybdic-phosphotungstic
reagents commercially prepared as Folin Ciocalteu's reagent.
Reagents
1. Na2C03 (2%) in 0.1 M-NaOH.
2. CuSQ+.5H20 (1%).
3. NaK tartrate (2%). -j
4. Fresh alkaline copper reagent prepared by mixing 1, 2 and 3 in
a ration of 100:1:1 by volume.
5. Folin-Ciocalteu1s reagent.
Procedure
Samples of 0.01 ml islet homogenate were diluted with 0.1 M-NaOH
to ensure that they were alkaline. Standard protein solutions of
0-300 yg albumen/ml were prepared from crystalline bovine albumen in
0.1 M-NaOH.
10 yl of unknown sample or protein standard was added to flat
bottomed tubes in duplicate. 1 ml of reagent 4 was added to each tube,
mixed and allowed to stand for 10 minutes for hydrolysis to take place.
100 yl of Folin-Ciocalteu's reagent was then added to each tube, mixed
and left to develop colour at room temperature for 1 hour. The opti¬
cal density of the blue solutions was read in a Unicam SP 1800
Ultraviolet Spectrophotometer at a wavelength of 750 nm. The absorption
of the standard protein solutions was plotted against their protein
concentration (Fig. 15) and the protein contents of the unknown samples















Figure 15 Standard solutions of crystalline albumin were assayed as
described in the text. The absorption of protein containing solutions
was read in an SP 1800 spectrophotometer at a wavelength of 750 nm.
Each point is the mean of duplicate observations.
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Electron Microscopy
Islets cultured with or without thyroxine were fixed with 3%
glutaraldehyde in 0.1 M-phosphate buffer, pH 7.4, post-fixed in 2%
osmium tetroxide and embedded in epoxy resin. This sections were
prepared and stained with a saturated solution of uranyl acetate in
50% ethanol before examination in a Jeol 100 S electron microscope.
Results
Insulin and Protein Content of Islets After Culture
The total insulin content of isJIets following 24 hour culture
with thyroxine (1 yg/ml) was no different from normal islets cultured
in the same conditions without thyroxine. The corresponding results
for insulin content were as follows: thyroxine treated = 16.0+2.03 ng
insulin/islet (55 observations); controls = 16.61±2.14 ng insulin/
islet (63 observations), p > 0.05. However, thyroxine treated islets
showed a significant diminution of total protein content, observed to
be 80% of normal. Protein content of controls was 1.71±0.19 yg
protein/islet (63 observations); protein content of thyroxine treated
islets was 1.39±0.12 yg proteiri/islet (55 observations) (p < 0.05).
Ultrastructure of Islets After Culture
Electron micrographs of randomly selected areas of islets which
had been cultured for 24 hours in the absence (Fig. 16) or in the
presence (Fig. 17) of 1.0 yg/ml thyroxine were examined, It is clear
that there were no major structural differences in either A or B cells
y '
between islets cultured in the presence or absence of thyroid hormones
In addition, the isolation and culture procedure had no adverse effect
-122-
Figure 16b (xSOOO magnification]
Electron micrographs of B cells from islets cultured for 24 hours
the conditions described in the text, without thyroxine.
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Figure 17a (x5400 magnification)
Figure 17b (x400G magnification^
Electron micrographs of B cells from islets cultured for 24 hours with
1.0 yg/ml thyroxine in the conditions described in the text.
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on the ultrastructure of A or B cells, whose appearance remained
closely similar to that seen in islets in whole pancreas (Fig. 12).
Discussion
There was no alteration in the insulin content of thyroxine
treated islets as compared to cultured controls, in accordance with
previous reports of a normal islet insulin content in experimentally
hyperthyroid ob/ob mice (Lenzen, 1978b). Similarities between the
effects of thyroid hormone treatment and starvation on B cells were
again apparent, in that starved animals also have a normal islet
insulin content (Malaisse, 1967e). In addition, the protein content
of islets cultured with thyroid hormones was reduced by 20% while
Levy reported a 12% reduction of protein content in islets from
starved rats (Levy, 1976). The decrease in islet protein content is
consistent with the predominance of protein catabolism over protein
synthesis, which is generally found in hyperthyroidism, particularly
in muscle tissue (Hoch, 1974).
The electron mi orographic studies demonstrated that tissue
culture of islets with thyroid hormones did not give rise to any
deleterious structural changes in B cells. This further excludes
the possibility that these hormones have a purely toxic effect, in
agreement with the results of histological examinations of the





THE LONG-TERM DIRECT EFFECT OF THYROID HORMONES ON (PRO)-INSULIN
BIOSYNTHESIS
Introduction
The long-term influences on insulin secretion by a variety of
agents are paralleled by comparable changes in insulin biosynthesis.
For instance, enhanced insulin secretion of late pregnancy (Green,
1972) is accompanied by an increased rate of insulin, synthesis (Bone,
1977) and starvation similarly impairs both glucose-induced insulin
secretion (Malaisse, 1967e) and biosynthesis (Andersson, 1974). At
present, there is scant information regarding the biosynthetic
capacity of B cells during hyperthyroidism. In view of the depression
of glucose-induced insulin secretion by thyroid hormones, and the close
interaction between mechanisms of hormonal secretion and production,
the following experiments were designed to investigate possible long-
term effects of thyroid hormones on insulin biosynthesis.
Methods
Isolated islets were cultured for 24 hours with or without
1 ug/ml thyroxine. They were then pre-incubated for 30 minutes in
bicarbonate-buffered medium, prior to their use in the experiments.
The (pro)-insulin biosynthetic capacity of the islets after culture
was measured by the method of Schatz et al. (1973).
(Pro)-Insul1n Biosynthesis
Groups of 40 islets were incubated in 1 ml bicarbonate-buffered
media with 2' rng/ml albumen, 17 naturally-occurring amino acids (20 pg/
ml of each amino acid excluding leucine), glucose to give concentrations
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of 6 or 20 mmol/1 arid 4-5-H3-L-leucine, 50 yCi/ml (58 Ci/mmol
specific activity). Incubations were carried out in 95% 02: 5% C02,
at 37°C for 3 hours with gentle shaking.
After incubation, the islets and the incubation media were
extracted together to measure the total synthetic capacity of the
islets. Ice-cold trichloroacetic acid (TCA) was added to the samples
to give a final concentration of 10%. The samples were sonicated for
10 seconds (MSE Ultrasonic Disintegrator) at high power, amplitude 3,
and the resultant precipitate was washed three times with 5% TCA con¬
taining 1 mg/ml unlabel led leucine. The final precipitate was
redissolved in 0.5 ml 1 M acetic acid.
Separation of the islet proteins in solution was achieved on a
Sephadex G-50 fine column, 1.2 x 100 cm, eluting with 1 M acetic acid
at a rate of approximately 10 ml/h. Fractions of 1 ml were collected,
1 ml of scintillation fluid (700 ml toluene:300 ml Triton X-l00:5 g
PP0) was added to 0.1 ml of each fraction, and the radioactivity was
counted. The two intermediate peaks obtained after separation of
TCA-precipitable islet proteins were identified as pro-insulin and
insulin by polyacrylamide-gel electrophoresis (Davis, 1964). Six
fractions of each peak from individual samples were pooled to estimate
the total counts per minute of radioactivity in the void volume, pro-
insulin and insulin peaks.
Polyacrylamide Gel Electrophoresis
Preparation of gel columns
Solution A: 48 ml 1 M HC1
36.6 g Tris
0.23ml Temed (N,N,N',N*-Tetramethylethyl-
enediamine) diluted to 100 ml, pH 8.9.
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Solution B: 32 g Acrylamide
0.8 g Bis-acrylamide, diluted to 100 ml
for 8% solution.
Buffer Solution C: 6.0 g Tris
28.8 g Glycine diluted to 1000 ml
used in 1:10 dilution.
Gel solution was made up by mixing 1 ml solution A, 2 ml solution B,
3 ml distilled water and 2 ml ammonium persulphate (0.14 g in 100 ml).
2 ml of gel solution was placed into each gel column and a small
amount of distilled water was layered on top of each gel to obtain a
flat interface. The columns were allowed to set.
Preparation of samples
The eluant fractions of peak 2 and peak 3 (Fig. 18) were pooled
into two separate samples, lyophilized and reconstituted with 150 yl
0.01 M HC1 together with porcine pro-insulin and bovine insulin markers.
Gel electrophoresis
When the gels had set,- the water was removed from the surface,
and the samples, mixed with bromophenol blue, were layered on top of
the gels, which were then topped up with Tris/glycine buffer
(solution C). Electrophoresis was carried out at room temperature
at 5 mA per tube. On removal from the gel columns the gels were
stained with 10% TCA and sliced at 3 mm intervals. Each slice was
dissolved in 0.2 ml of 100-volume H2C^at 60° C for 8 hours. 2 ml of
Triton-based scintillant (700 ml toluene:300 ml Triton X-100: 5 g
PP0) were added to each sample, and they were assayed for radio¬
activity. The pro-insulin and insulin markers were observed as white






Figure 18 The effect of glucose (6 or 20 mmol/1) on the incorporation
of H-3-leucine into the proteins of isolated islets. The islets were
cultured for 24 hours with 1 ug/ml thyroxine prior to incubation with
glucose. Following precipitation with trichloroacetic acid., the islet
proteins were fractionated on a Sephadex 6-50 fine column. Mean
curves are shown, derived from three experiments each.
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Results
The incorporation of H-3-leucine into islet proteins at 6 or
20 mmol/1 glucose is shown in Fig. 18. The elution pattern from the
Sephadex column forms three major peaks. The first peak represents
the void volume eluted with dextran blue. Polyacrylamide gel electro¬
phoresis of pooled fractions of the second and third peaks is shown
in Fig.19 and Fig.20* The intermediate peak gave the greatest radio¬
activity in the area of the pro-insulin marker (Fig. 19) while the
bulk of radioactivity of the third peak coincided with the insulin
marker (Fig. 20). Thus, the intermediate peak and the last peak com¬
prise the incorporation of labelled leucine into pro-insulin and
insulin respectively. It has previously been observed that the radio¬
activity recovered in the insulin region includes the radioactivity of
C-peptide, which is eluted together with insulin from Sephadex G-50
columns (Sando, 1972).
In the control islets the incorporation of radioactivity into
TCA-precipi table non-specific proteins eluted with the void volume was
not significantly affected by increasing the glucose concentration from
6 to 20 mmol/1 (Table IVa and IVb). However, the uptake of H-3-leucine
into the pro-insulin and insulin fractions rose by 66% with an
increased concentration of glucose. 24 hour culture with thyroxine
did not affect the pro-insulin and insulin biosynthetic capacity of
islets at 6 mmol/1 glucose (Table IVa), but, incubation in 20 mmol/1
glucose resulted in a significant (p < 0.005) 41% inhibition of non¬
specific protein biosynthesis by thyroid hormones (Table IVb). In
the presence of this concentration of glucose the thyroxine treated





Figure 19 Polyacrylamide gel electrophoresis of protein fractions
constituting the second peak collected after elution of TCA-
precipitable islet proteins labelled with H-3-leucine, from a control
sample of cultured islets5 on a Sephadex G-50 column. Porcine pro-
insulin and bovine insuline were added to the samples as markers. The
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Figure 20 Polyacrylamide gei electrophoresis of protein fractions
constituting the third peak collected after elution of TCA-precipitable
islet proteins labelled with H-3-leucine, from a control sample of
cultured islets, on a Sephadex G-50 column. Porcine pro-insulin and
bovine insulin were added to the samples as markers. The maximum
radioactivity of the third peak was associated with the insulin
marker.
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TABLE IVa and IVb
Effect of 24 hour culture with thyroxine (1 ug/ml) on the subsequent
incorporation of radioactivity into 3 fractions of islet proteins in
response to 6 or 20 mmol/1 glucose. After culture islets were
incubated for 3 hours in bicarbonate-buffered media containing 6 or
20 mmol/1 glucose, albumen and 50 pCi/ml H-3-leucine. TCA-precipitabl
proteins were separated on a Sephadex G-50 fine column. The radio¬
activity of the protein, pro-insulin and insulin peaks was estimated
by pooling 5 eluted fractions constituting each peak. The mean
values of the total counts per minute in the pooled peaks are shown
± SEM of the number of observations in parentheses. The observed
difference between paired control and thyroxine treated samples (c.p.m
is calculated as a percentage of the control value, and is expressed as












Pro-insulin 6,357± 971 5,740±1,422
(4) (4)
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Pro-insulin 9,835±2,300 5,815± 855
(4)










insulin synthesis (Table IVb). The pro-insulin uptake of H-3-leucine
reaches a steady state within a few hours of incubation, while
labelling of the insulin pool continues at a linear rate for at
least 12 hours (Steiner, 1959). Therefore, any increase in the ratio
between the total radioactivity in pro-insulin and insulin and that
in insulin alone reflects a change in the rate of conversion of pro-
insulin. The results show that, despite an inhibition of pro-insulin
synthesis at high concentrations of glucose by thyroid hormones, there
was no appreciable effect on the degree of conversion of pro-insulin
to insulin, which was maintained at approximately 40%, and the
incorporation of radioactivity into insulin at the end of the incu¬
bation period with 20 mmol/1 glucose was unaffected (Table IVb).
Discussion
Glucose has been shown to promote amino acid incorporation into
rabbit pancreas slices (Parry, 1956), and isolated islets (Howell, 1966;
Morris, 1970), by preferential stimulation of pro-insulin and insulin
biosynthesis (Morris, 1970; Bone, 1977). The effect is rapid and
appears to depend on a selective enhancement of tRNA rather than
synthesis of new mRNA (Bone, 1977). Although the uptake of labelled
amino acids into other islet proteins is also dependent on the pres¬
ence of glucose, the influence of increasing glucose levels is
relatively insignificant, as was the case in these experiments,
whereas there is marked concurrent stimulation of pro-insulin and
insulin synthesis (Schatz, 1973).
"j»
In addition to the changes of B cell insulin secretion incurred
during a period of tissue culture, the alterations of glucose sensi¬
tivity are reflected in the pattern of hormonal synthesis by isolated
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islets. Unless the islets are cultured in media containing a high
concentration of glucose, there is an overall reduction in (pro)-
insulin biosynthesis, although the characteristic ratios of amino
acid incorporation into pro-insulin and insulin are not grossly
affected (Andersson, 1974). Furthermore, after tissue culture the
islets do not show the same marked increase in insulin biosynthesis,
which generally accompanies a rise in glucose concentration in freshly
isolated islets (Andersson, 1974).
In the experiments here, the biosynthesis of (pro)-insulin by
control islets was increased in 20 mmol/1 glucose, but the rise was
not statistically significant. This was possibly due to the large
standard errors inherent in this particular method of separating
islet proteins. However, thyroid hormones evidently exert a highly
significant (p < 0.005) inhibitory effect on the synthesis of TCA-
precipitable proteins and pro-insulin, when compared to non-treated
islets at a raised concentration of glucose. It is possible that
thyroid hormones stimulate the breakdown of islet proteins with a
consequent increase in the intracellular pool of free amino acids.
This may lead to a dilution of the free H-3-leucine pool and a
decrease in the observed incorporation of radioactivity into (pro)-
insulin. It has been suggested that this phenomenon occurs in
starvation (Gylfe, 1974), but isotope dilution seems unlikely in the
above experiments, since incubation of islets with thyroid hormones
did not alter the incorporation of labelled leucine into TCA-
precipitable proteins at a physiological concentration of glucose.
Thus the changes in (pro)-insulin biosynthesis produced by
thyroid hormones are again analogous to the decreased biosynthesis of
(pro)-insulin observed in islets from starved animals (Tijoe, 1976;
Bone, 1977), or isolated islets cultured in low glucose concentrations
(Andersson, 1974 and 1576a), although the effect of starvation on
total islet protein synthesis remains controversial (Levy, 1976;
Bone, 1977). The conversion of pro-insulin to insulin is a process
which does not require the presence of glucose (Steiner, 1972;
Jain, 1977), but may be activated by high concentrations of glucose
(Jain, 1977; Andersson, 1974). Neither thyroid hormones nor star¬






THE LONG-TERM EFFECT OF THYROID HORMONES ON ISLET ADENYLATE CYCLASE
ACTIVITY
Introduction
It has been proposed that an increased sympathetic activity may
account for some of the features observed in hyperthyroidism and that
the action of thyroid hormones is mediated through catecholamines
(Brewster, 1956). The possibility that thyroid hormones enhance the
tissue response to catecholamines through t'ne adenylate cyclase-cyclic
AMP system was investigated in epididymal fat pads from hyperthyroid
rats (Krishna, 1968). These authors concluded that thyroid hormones
induce the formation of adenylate cyclase in adipose tissue, thus
potentiating catecholamine effects. Many analogies can be drawn between
the changes in islet function due to the prolonged lack of an adequate
glucose stimulus, and the long-term effects of thyroid hormones already
demonstrated. A diminution of adenylate cyclase activity is strongly
implicated as at least one of the causal events leading to the reduced
insulin secretion and biosynthesis in starvation (Howell, 1973b).
Furthermore, the reversal of thyroxine-induced inhibition of insulin
secretion by theophylline (Chapter 4) also suggests that the adenylate
cyclase-cyclic AMP system may be involved. Thyroid hormones do not
appear to significantly alter islet ATP levels (Lenzen, 1978b), nor the
activity of phosphodiesterase in adipose tissue (Krishna, 1958).
Therefore, it seemed important to establish whether islet adenylate
cyclase activity was affected.
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Methods
Isolated islets from non-fasted euthyroid animals were cultured
for 24 hours with or without 1.0 pg/ml thyroxine as previously
described. At the end of the culture period, they were washed three
times in bicarbonate-buffered medium prior to their use in the
experiments.
The activity of islet adenylate cyclase was measured by the
method of Howell and Montague (1973a) using a broken cell preparation
which is incubated in the presence of labelled ATP, and separating
the newly formed labelled cyclic AMP on a neutral alumina column.
The adenylate cyclase of the broken cell preparation shows a marked
stimulation with 10 mM sodium fluoride, although the mechanism of
this effect is uncertain, and the activity of adenylate cyclase.in the
presence of NaF indicates the total amount of enzyme present
(Montague, 1975b).
Two buffers were made up as follows:-
Buffer A: 25 mM Tris HC1; 5 mM MgCl2; 1 mM EDTA.
Buffer B: 25 mM Tris HC1; 1 mM EDTA; 0.1% (w/v) albumen,
5 mM MgCl2; 1 mM isomethylbutyl xanthine;
1 mg/ml creatine phosphokinase, 7 mg/ml
phosphocreatine; 10 pM ATP and 20 pi/ml
(ct-32p) ATP.
After tissue culture, batches of 50 islets were homogenised
using a glass homogeniser in 0.5 ml buffer A.
„ 50 pi of buffer B was added to assay tubes, with or without
10 pi NaF (10 mM). 50 pi of islet homogenate was then placed in each
tube and the tubes were incubated at room temperature for 30 minutes.
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The reaction was terminated at the end of this period by placing the
tubes in a boiling water bath for 3 minutes. 50 yl of 1 mg/ml
unlabel!ed cyclic AMP was then added to each tube as a carrier, and
the contents of the tubes were run through alumina columns, eluted
with 5 ml of 10 mM Tris HC1 (pH 7.6J. This separated the:newly
synthesised cyclic [32P]AMP, which was collected with the eluant in
scintillation vials, and counted for radioactivity. All observations
were in triplicate. The protein concentration of 50 yl of each islet
homogenate was measured by the method of Lowry (1951).
Results
Estimations of adenylate cyclase activity of islet homogenates
after 24 hour incubations with thyroxine (1 yg/ml) are shown in
Table V. Basal values of adenylate cyclase activity after tissue
culture were low, but adequate stimulation of activity was achieved
with sodium fluoride. There was no significant effect of thyroid
hormones on either the basal or stimulated adenylate cyclase activity.
Discussion
The low basal values of adenylate cyclase activity in both
control and thyroxine treated islets were probably a consequence of
tissue culture; the glucose stimulated rise in cyclic AMP observed in
freshly isolated islets is not apparent in islets after tissue culture,
despite their maintenance at a physiological glucose concentration
(k'abinovitch, 1978J. Thyroid hormones did not significantly affect
the basal enzyme activity, nor did they, influence the maximal adenylate
cyclase activity demonstrated by stimulation with sodium fluoride,
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TA8LE V
Adenylate cyclase activity of rat islet homogenates after 24 hour
culture of islets with or without thyroxine (1 ug/ml). Enzyme
activity at basal control value and after stimulation with sodium
fluoride is expressed as pmoles cyclic AMP formed/mg protein/20 min
± SEM of the number of observations in parentheses.
Control Thyroxine
T pg/ml
Basal control 0.88±0.74 1.43±0.82
(4) (5)
NaF stimulation 17.95+1.64 18.65±3.15
10 mmol/1 (5) (5)
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when islets v/ere cultured in the presence of 5.5 mmol/1 glucose.
Many of the hormonal adjustments of insulin secretion are
made through modifications of adenylate cyclase activity. This
enzyme can be regulated by the interaction of hormones with specific
receptor molecules at the B cell plasma membrane (Goldfinch, 1972;
Sharp, 1979). Polypeptide hormones such as ACTH, glucagon, secretin
and pancreozymin stimulate adenylate cyclase activity and raise intra¬
cellular cyclic AMP (Sharp, 1979). Consequently, insulin release in
response to glucose is potentiated through the augmentation of the
calcium-dependent secretory events (Montague, 1977; Sharp, 1979).
Insulin itself exerts a negative feedback inhibition on the B cell,
and so far is the only hormone known to depress adenylate cyclase
activity in islets (Kuo, 1973). Somatostatin and a-adrenergic agents
are also purported to lower cyclic AMP levels by inhibition of
adenylate cyclase (Kuo, 1973; Howell, 1973a; Efendic, 1978), but this
has been disputed since raising cyclic AMP or activating adenylate
cyclase does not reverse the blocked insulin release produced by these
agents (Malaisse, 1970a; Gerich, 1977).
Isolated islets from pregnant rats also have an increased
adenylate cyclase.activity (Green, 1973), which presents a possible
explanation for the enhancement of insulin release in response to
gestational hormones (Howell, 1977).. However, pregnant rats in pair-
feeding experiments with control animals did not show a comparable
magnitude of insulin secretion as did pregnant rats on an unrestricted
diet (Green, 1974). Therefore, at least part of the effect of preg¬
nancy on insulin release can be accounted for by the 20% rise in food
intake during late gestation (Green, 1972).
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It is now evident that the long-term influence of carbohydrate
ingestion on insulin secretion, as manifest during starvation or
glucose-loading, is accompanied by alterations in islet adenylate
cyclase activity (Howell, 1973b) and glucose metabolism (Levy, 1976).
It was originally suggested that the poor insulin response to glucose
in rats fasted for 48 hours was due to changes in a glucose-inducible
enzyme system, since the restoration of normal insulin secretion was
blocked by actinomycin D (Grey, 1970). Certainly, basal and glucagon-
stimulated adenylate cyclase activity is reduced by starvation
(Howell, 1973b). In addition, the lack of a glucose induced rise in
cyclic AMP in islets from starved rats, which precedes any alterations
in glucose metabolism (Wolters, 1977), and the restoration of normal
insulin release by phosphodiesterase inhibitors (Grey, 1970),
implicates the adenylate cyclase-cyclic AMP system in the starvation
induced changes of insulin secretion, rather than a defect in glycoly¬
sis (Bouman, 1979). This may also account for the reduced insulin
biosynthesis in starvation (Bone, 1977), since cyclic AMP appears to
have a regulatory role on the glucose sensitive insulin-synthesising
mechanism (Maldonato, 1977). Conversely, the long-term trophic
effect of glucose on insulin Secretion is reflected in the rise in
adenylate cyclase activity after exposure of B cells to hyperglycaemia
(Howell, 1973b) or high glucose concentrations in vitro (Howell, 1973b;
Andersson, 1972).
In view of the changes in the pattern of insulin secretion and
biosynthesis produced by thyroid hormones, and its similarity to that
observed after starvation, it seemed possible that thyroid hormones
could evoke alterations in cyclic AMP though a direct effect on
adenylate cyclase activity. The results have failed to show any
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significant change in the activity of this enzyme, in keeping with
other reports of a lack of effect of thyroid hormones on adenylate
cyclase activity in the hepatic and cardiac tissue from hyperthyroid
animals (Jones, 1972; Sobel, 1969). Cyclic AMP concentrations may be
affected by substrate ATP availability. However, despite a 20% fall
in the hepatic ATP content of euthyroid rats treated with tri¬
iodothyronine (Ismail-Beigi, 1973), a similar decrease has not been
found in the endocrine pancreas (Lenzen, 1978b), liver (Chilson, 1959)
and heart muscle (Piatnek-Leunissen, 1967) from hyperthyroid animals.
In these experiments, the finding that insulin secretion, itself an
ATP dependent process, can be restored by theophylline makes an overall
i-
fall in cellular ATP concentration seem unlikely. However, thyroid
hormones may lead to a speculative fall in local ATP levels close to
the plasma membrane. The existence of a local pool of ATP has pre¬
viously been suggested in rat muscle cells (Reporter, 1972) and rat
superior cervical ganglia (Lindl, 1975). Davis and Lazarus (1976)
have reinforced this theory using in vitro preparations of mouse islet
B-granules and cod islet plasma membranes. Their studies on the con¬
ditions leading to granule-membrane interactions and subsequent insulin
release suggest that compartmentation of ATP at the plasma membrane is
crucial both for initiating and maintaining insulin secretion. Thus,
if such a membrane-associated ATP pool was reduced by thyroid hormones,
the additional stimulus produced by theophylline, in raising cyclic AMP





Thyroid hormones are known to impair glucose tolerance.
Hyperthyroidism may precipitate overt diabetes in susceptible
animals (Houssay, 1944 and 1948)and humans (Regan, 1940), and frequently
exacerbates the metabolic derangement in pre-existing diabetes (Lakin,
1961). Various theories put forward to explain these phenomena have
failed to differentiate between the possible primary effects of an
excess of thyroid hormones on insulin secretion, and the multitude of
diverse metabolic changes that occur in hyperthyroidism, with second¬
ary sequelae. . Consequently, Hn vivo' studies of hyperthyroidism and
carbohydrate tolerance have yielded complex and contradictory results.
The work here has, within the methodological limitations outlined
below, contributed both to the biochemical information of the basis
of thyroid hormone and B cell interactions, and to clinical under¬
standing of the relationship between hyperthyroidism and diabetes.
Methodological Considerations
The development of organ culture techniques for endocrine
pancreatic tissue has encouraged an Hn vitro* appraisal of insulin
secretion, and has made it possible to examine the direct effects of
any one factor on B cell function, whilst maintaining the stability
of cellular surroundings. How far one is justified in extrapolating
the conclusions from this particular approach to the intact animal
is still questionable. Living tissues exist in dynamic interactions,
and this has to be borne in mind when interpreting such xin vitro'
models. Nevertheless, these methods have provided a valuable way
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to disentangle the numerous elements involved in the control of
hormone release.
The following considerations emerged in a retrospective analysis
of experimental methods:-
1. The tissue culture technique used in this study demonstrated the
general drawbacks which are known to occur in the lin vitro' mainten¬
ance of tissues other than islets; although cellular viability is
retained, there is a loss of the more specific features of cellular
activity. In this case, the sensitivity and capacity of islets to
respond to glucose was diminished, even after 24 hours. It seems that
indeterminate constituents of serum can abrogate these disadvantages
to some degree (Whittaker, 1977; Andersson, 1978), and in retrospect,
perhaps a higher concentration of serum should have been included in
the tissue culture media. The maintenance of islets in artificial
capillary units (Amikon Ltd.) with continuous perfusion in fresh
medium (Tze, 1977) may provide a means of producing a closer approxi¬
mation to stable physiological conditions.
2. The measurement of (pro)-insulin biosynthesis (Chapter 6) by gel
filtration of TCA-precipitable islet proteins did not give highly
accurate results. It has now been superseded in most laboratories by
the use of anti-insulin serum covalently coupled to a solid phase,
usually cyanogen bromide-activated Sepharose 4B (Pharmacia Ltd.)
which is used to separate immunoreactive pro-insulin and insulin from
other islet proteins (Berne, 1975). However, attempts to utilise the
latter technique proved unsuccessful. Sepharose-bound normal guinea
pig serum designated as a control in the separation of (pro)-insulin
had a high binding affinity for radio-labelled islet proteins, so that
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consistent control values of non-specific binding to Sepharose could
not be achieved, and therefore an alternative method was used.
3. In the present study the extracellular concentration of free
thyroxine was approximately 10~8 M, a thousand fold higher than exists
in the euthyroid state 'in vivo', and some free tri-iodo-thyronine
was also present (2 x ICT10 M). This raises the question of whether
the observed effects have a physiological relevance. However, it
should be noted that in general, studies of the effects of thyroid
hormones on intracellular events have used hormone concentrations often
greater than 10"7M (Rail, 1953 and 1978; Buchanan, 1971; Gordon, 1973;
Goldfine, 1975). With rare exceptions (Siegel,1972) doses of thyroid
hormones required to produce a particular effect 'in vitro' are
several thousand fold greater than those necessary to establish a
comparable effect 'invito' (Goldfine, 1975).
Therefore, the use of high thyroid hormone concentrations is
established practice, and there is no reason to suppose that the
results on isolated islets are less physiologically relevant than
other studies of thyroid hormone actions.
The Effects of Thyroid Hormones on B Cell Function
The long-term regulation of insulin secretion is not only
evident in starved (Grey, 1970) and pregnant (Green, 1972) animals,
but is also manifest in vitro after maintaining isolated islets with
high or low concentrations of glucose (Howell, 1973b; Andersson, 1974),
progesterone (Howell, 1977) and growth hormone (Whittaker, 1977a J
Alterations in insulin release resulting from experimentally induced
hyperthyroidism in rats (Malaisse, 1957c; Lenzen, 1975) might
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represent a similar long-term influence of thyroid hormones on
pancreatic B cells. By using a tissue culture system for isolated
islets from euthyroid rats, it v/as possible to investigate the direct
effects of thyroid hormones on islet function, without the secondary
metabolic complications of hyperthyroidism.
The present studies on the short-term influence of thyroid
hormones on isolated islets showed that thyroid hormones, in the con¬
centrations used, had no immediate effect on insulin secretion in
response to glucose. However, after 24 hour exposure of islets to
the presence of thyroid hormones, both the subsequent glucose stimu¬
lated insulin biosynthesis, and secretion were significantly reduced.
This effect was apparent at higher concentrations of glucose (20 mmol/1)
and was consistent with similar reports of selective inhibition of
insulin secretion from pancreatic pieces or the perfused pancreas from
hyperthyroid rats (Malaisse, 1967c; Lenzen, 1975). These observations
may have been reflected in a fall in islet insulin content after
thyroxine treatment. While this work was in progress, Lenzen reported
that hyperthyroid ob/ob mice did not develop changes in the insulin
content of isolated islets, although he detected a fall in total
pancreatic insulin content, and postulated a reduction of individual
islet cell volume in relation to the total pancreatic parenchyma,
probably due to shrinkage of B cells rather than a quantitative change
in cell number (Lenzen, 1978b). In accordance with this proposal,
rat islets treated with thyroid hormones for 24 hours in vitro also
had a normal insulin content, but a 20% fall in protein content. A
lack of degenerative changes in the islets from hyperthyroid ob/ob
mice on histological examination (Lenzen, 1978b), together with the
normal ultrastructural appearance of thyroxine treated rat islets,
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precludes the possibility of a simple toxic effect of thyroid
hormones on B cells. In addition, the reversibility of the suppression
of glucose induced insulin secretion in thyroxine treated islets by
theophylline, or by intermediates of glycolysis in islets from hyper-
thyroid rats (Lenzen, 1975a), further implies a specific effect of
thyroid hormones on B cell metabolism.
The characteristics of islets resulting from thyroid hormone
treatment are strikingly similar to those observed after starvation
(Malaisse, 1957e; Levy, 1975). Malaisse and collaborators have pro¬
posed that reduction of glucose phosphorylating activity and of
phosphofructokinase in B cells may be critically important in
mediating the reduced secretory response of islets from starved rats
(Levy, 1975). Reports of thyroid hormone action on carbohydrate
metabolism almost uniformly suggest that an increase in glucose oxi¬
dation and glycolysis occurs (Hoch, 1974; Lenzen, 1978b), so that a
reduction of glycolytic activity of the type demonstrated in starvation
(Malaisse, 1976) would be unlikely to account for the inhibition of
insulin secretion by thyroid hormones. Adenylate cyclase activity is
reduced in islets from starved animals, probably as a result of hypo-
glycaemia (Howell, 1973b). Glucose normally exerts a long-term
"trophic" influence on this enzyme in islets (Howell, 1973b), and in
the presence of a normal glucose concentration, thyroid hormones did
not elicit a similar change in adenylate cyclase activity.
Possible Mechanisms of Thyroid Hormone Action on B Cell Metabolism
Magnus-Levy introduced the fundamental observation in 1895 that
oxygen consumption was higher in hyperthyroid patients. Originally,
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thyroid hormones were postulated to uncouple mitochondrial oxidative
phosphorylation (Loomis and Lipman, 1948), but this hypothesis has not
been upheld. Coupled oxidative phosphorylation was demonstrated in
mitochondria from hyperthyroid patients (Stocker, 1958), and
thyroxine administration in vivo increased the respiratory and
phosphorylating capacity of rat mitochondria (Tata, 1963; Gustafsson,
1965). In fact, the actions of thyroid hormones at the intracellular
level are so diverse that no single coherent explanation exists at
present to account for all the observed effects. A wide variety of
binding proteins for thyroxine and tri-iodo-thyronine have been
identified in the cytosol and nuclear material of several tissues
known to be sensitive to thyroid hormones (Rail, 1978). Generally, it
is held that thyroid hormones enhance the synthesis of messenger RNA
by binding to nuclear proteins, with possibly similar, but at present
still obscure, effects on mitochondrial protein synthesis (Tata, 1966;
Rail, 1978). The net result is the induction and increased activity
of various enzyme systems, including the glycolytic enzymes,
a-glycerophosphate dehydrogenase being the most strikingly affected
(Rail, 1978).
Recent evidence suggests that thyroid hormones regulate oxygen
consumption and thermogenesis by stimulating the mechanisms involved
in maintaining the intracellular ionic composition of hormone-
sensitive tissues (Ismai1-Beigi, 1977). Cells establish and maintain
a constant potential difference through the selective transport of
Na+ and K+ ions. The membrane-bound Na+ K+-ATPase enzyme system con¬
stitutes an integral part of this process, and 20-45% of the total
cellular energy expenditure is used by this 'sodium pump' (Skou,
1965; Glynn, 1975). Thyroid hormones increase sodium pump activity.
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Muscle tissue from experimentally hyperthyroid rats has a raised
membrane potential difference for sodium and potassium, and a fall in
intracellular sodium (Ismail-Beigi, 1971). Studies on 22Na+ pre-
labelled rat liver slices show that the rate of sodium efflux is
stimulated in hyperthyroidism (Ismail-Beigi, 1973). Finally, direct
measurements of Na+ K+-ATPase in rat skeletal, hepatic and renal
tissue after administration of tri-iodo-thyronine to euthyroid animals
show a significant increase in Na+ K+-ATPase activity (Israel, 1973;
Ismail-Beigi, 1977). Thus a major mode of action of thyroid hormones
is the stimulation of energy utilisation by activating transmembrane
sodium transport, leading in turn to increased ADP formation and a
consequent rise in mitochondrial oxygen consumption (Rail, 1978).
The implications of such a theory of thyroid hormone action are
two-fold in respect to B cell function. Firstly, Na+ K+-ATPase has
been identified in the plasma membrane fractions of rat pancreatic
islets (Lernmark, 1975; Kemmler, 1977), with an activity comparable
to that in other mammalian tissues (Kemmler, 1977). A thyroid hormone
stimulated rise in enzyme activity could result in the reduction of a
hypothetical membrane-associated ATP pool (Davis, 1975) through
enhanced adenine nucleotide dephosphorylation, and reduced cyclic AMP
production, as discussed in Chapter 7.
Secondly, the control of sodium entry into the B cell may be a
fundamental event in the stimulation of insulin secretion (Milner,
1957). Insulin release is influenced both by intra- and extracellular
sodium concentrations. Low extracellular sodium inhibits insulin
secretion (Hales, 1958a), and agents such as oubain, or high extra¬
cellular potassium, which raise intracellular sodium, potentiate
insulin release (Hales, 1968a and 1968b). Current evididence suggests
that sodium influx into the B cell modulates the cytosolic calcium
concentrations (Lowe, 1976; Donatsch, 1977), which may itself be an
essential event in the initiation of insulin secretion (as outlined
in Chapter 1). Measurements of islet insulin release in the presence
of classical potentiators or inhibitors of the sodium permeability of
excitable membranes, such as veratridine (Ohta, 1973) or tetrodotoxin
(Donatsch, 1977), indicate that a similar mechanism operates for
calcium translocation in the B cell as in the giant squid axon
(Donatsch, 1977).
The B cell membrane is depolarised by a glucose stimulus (Dean,
1970), and calcium enters the cell as part of this electrochemical
event (Donatsch, 1977). Early in the generated action potential, the
patent sodium channels allow calcium entry. Membrane depolarisation
enhances further calcium influx late in the action potential, through
voltage-dependent calcium channels. These can be blocked by cobalt
chloride or D600 (Baker, 1975), and the subsequent reduction of insulin
release (Henquin, 1975; Malaisse, 1976a) implicates the voltage-
dependent channels as being the most significant means of calcium entry
(Donatsch, 1977). Consequently, the activity of the sodium pump may
represent an important factor in the control of membrane permeability
to calcium. The sodium-calcium counter transport system (Blaustein,
1974) may also be involved in modulating cytosolic calcium levels,
through the inhibition of calcium efflux, as a result of an increased
competition for the transmembrane carrier by high intracellular sodium
(Donatsch, 1977). Intracellular potassium levels are also important
for insulin secretion (Hales, 1968a); it has been postulated that
early membrane depolarisation is due to a reduction in the potassium
permeability of the B cell membrane (Henquin, 1978), since glucose
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markedly diminished the efflux rate of 42K+ from prelabelled islets
(Henquin, 1978).
In summary, the Na+ K+-ATPase system may constitute an integral
part of the regulation of B cell cytosolic calcium concentration.
Despite the lack of effect of important insulin secretagogues, includ¬
ing glucose and sulphonyl ureas, on Na+ K+-ATPase activity (Kemmler,
1977), the function of the enzyme is altered by other agents influential
in B cell secretion. Oubain inhibits Na+ K+-ATPase activity in rat
pancreatic islets (Kemmler, 1977). Interestingly, although the
observation has not been verified in pancreatic islets, cyclic nucleo¬
tides are highly effective inhibitors of Na+ K+-ATPase in rat liver
plasma membranes (Tria, 1974) and human gastric mucosal cells (Mozsik,
1970). Of the. various cyclic nucleotides tested, cyclic AMP was the
most effective and its inhibitory action was further reinforced by
theophylline (Tria, 1974). In the absence of cyclic nucleotides,
phosphodiesterase inhibitors per se depressed Na+ K+-ATPase activity
(Tria, 1974).
Thus, thyroid hormone induction of Na+ K+-ATPase activity or
reduction of cyclic AMP levels, may have profound effects on movements
and concentrations of cations, in particular through decreasing cyto¬
solic calcium accumulation. Consistent with this is the finding of a
significant decrease in glucose stimulated k5Ca++ uptake in islets
from hyperthyroid ob/ob mice, after fasting for three days (Lenzen,
1978b), but further evidence of changes in B cell calcium regulation
in hyperthyroidism is required to substantiate this hypothesis. It
is not known whether the reduction in islet cyclic AMP levels in
starvation (Bouman, 1979), through alterations in adenylate cyclase




The long-term influence of thyroid hormones on pancreatic
islets described in this work has important clinical implications.
The possible development of diabetes mellitus during uncontrolled
hyperthyroidism should be borne in mind, particularly in view of the
similarity of some of the clinical features of both diseases.
Although the inhibition of insulin secretion brought about by
thyroid hormones may not be evident during fasting, it may be that
B cells cannot respond adequately to the fluctuations in blood
glucose levels, which result from the effect of an excess of thyroid
hormones on other tissues. This is particularly evident shortly
after meals when hyperthyroid patients show raised blood sugar levels
(Loeb, 1978). Both the results presented here and the observations on
pancreata from hyperthyroid animals (Lenzen, 1978a) indicate that the
adverse effect of thyroid hormones on B cell function occurs at higher
glucose concentrations. Thus, a consistently poor insulin response
to carbohydrate intake may ultimately lead to the irreversible
"exhaustion" of B cells which was proposed by Houssay. In his experi¬
ments with partially depancreatectomised dogs, he demonstrated that
"thyroid diabetes" could progress to permanent B cell destruction if
administration of thyroid extracts to the animals was continued
(Houssay, 1944 and 1948). This suggests that the duration of excess
circulating thyroid hormones may have repercussions on the reversi¬
bility of alterations in B cell function. Perhaps the conflicting
data on subsequent glucose tolerance when hyperthyroid patients
become euthyroid is a reflection of this, since authors have rarely
reported the estimated duration of abnormal thyroid function when
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assessing their conclusions. Also, as mentioned earlier, the
higher incidence of diabetes in patients with toxic nodular goire
rather than Graves' disease (Regan, 1940) may be due to the earlier
treatment of the latter group, who tend to exhibit more pronounced
signs of hyperthyroidism. Therefore, hyperthyroidism should be
promptly controlled, and a surveilance kept for carbohydrate intoler¬
ance. Similarly, in diabetic patients, metabolic instability can be
a sign of the onset of concurrent hyperthyroidism, and may indicate
further B cell damage.
Further research into thyroid hormone action on pancreatic islets
may add to the current theories of the long-term control and mechanisms
of insulin secretion. Insulin secretion from the perfused pancreas of
hyperthyroid rats is in many ways reminiscent of the pattern of
secretion in non-insulin dependent diabetes (Lenzen, 1978a) and this
has led to the suggestion that hyperthyroid animals could constitute a
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THE USE OF PILOCARPINE TO ENHANCE ISLET YIELD FROM RAT PANCREAS
Introduction
The low yield of islets that was obtainable from each rat
pancreas presented a problem throughout the experiments described in
this thesis, and is one of the major drawbacks in studies using iso¬
lated islets. In general, less than 20% of the endocrine pancreas can
be separated from exocrine tissue using current techniques.
Kuo and colleagues (1973) achieved significant improvements in
the .yield of isolated islets by pretreatment of animals with pilo¬
carpine to reduce the exocrine enzyme content, but their-method has
not been widely adopted for studies of islet metabolism lin vitro1
because of alterations in insulin secretion from islets isolated in
this way (Atkins, 1975). We have investigated the feasibility of
using pilocarpine to enhance islet yield in more detail, and attempted
to reverse the possible deleterious effects of pilocarpine on islet
function by maintaining islets in tissue culture following isolation.
Methods
Pretreatment of rats and islet isolation
Fed rats (inbred WAG strain, 200-250 g) were injected
intraperitoneally with a solution of 4% pilocarpine (Sigma, London)
in normal saline (40 mg/kg body weight), 1-1| hours prior to sacrifice
by cervical dislocation, and their pancreata were removed for islet
isolation by the collagenase digestion procedure described in Chapter 2.
A standard bicarbonate-buffered medium (Gey and Gey, 1935.) containing
5.5 mmol/1 glucose and gassed with 95% 02: 5% C02 was used throughout,
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and the number of islets was noted at each isolation.
Insulin content of islets during 24-hour tissue culture
The insulin content of isolated islets from control and
pilocarpine pretreated rats was determined at isolation and after
tissue culture. According to the previously described method, the
islets were incubated in TCM 199 supplemented with 5% new-born calf
serum, antibiotics and glucose to achieve a concentration of
20 mmol/1, at 37°C. Groups of islets were removed and homogenised
in acid-ethanol (as described in Chapter 5) at 0, 2, 4, 6 and 24 hours
of culture and the extracted insulin was measured by immunoassay
(Chapter 2).
Pancreatic morphology
Freshly isolated islets from pilocarpine pretreated animals
were prepared as described in Chapter 5 for examination under the
electron microscope.
Transplantation of islets
Streptozotocin 6 5 mg/kg in 0.05 M citrate buffer (pH 4.5) was
injected into the tail vein of inbred WAG rats (200 g), at least 2
weeks prior to their use as recipients of transplanted islets. Only
animals with at least 2 successive random blood glucose levels over
20 mmol/1 and a urine volume greater than 50 ml/24 hours were used.
1000 or more islets, isolated from 4 pilocarpine pretreated
donors, were suspended in 2 ml bicarbonate-buffered medium and
injected into the superior mesenteric vein of a diabetic recipient
(Fig. 21). The recipients were covered with penicillin (150,000 i.u.
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r"'S'jre 21 Intraportal transplantation of rat islets. Isolated islets
were injected into the superior mesenteric vein of a diabetic rat
recipient, through a 25 G butterfly needle.
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procainePenici11 in, 150,000 i.u. benzathine penicillin) for 48 hours
post-operatively, and their blood glucose concentrations and 24-hour
urine volumes were subsequently measured at regular intervals. Blood
glucose estimations were performed on non-fasting morning samples of
blood using a glucose oxidase method (God-Perid, Boehringer, London).
Results
Islet yield and insulin content
The collagenase procedure for isolation of islets gave a mean
of 686+45 islets in 10 consecutive isolations from groups of 4 non-
pi locarpine pretreated control donors. Pretreatment of rats with
pilocarpine significantly increased the mean islet yield to 1189±34
from 4 pancreata in 34 successive isolations (p < 0.001).
Fig. 22 shows the insulin content of islets at isolation and
after 24 hours. The insulin content of freshly isolated islets from
pilocarpine pretreated donors was considerably lower than that of
controls (p < 0,05). The insulin content of control islets fell
progressively during the 24 hour culture period (Fig. 22), and the
final content was 60% of the original (p < 0.001). However, the dis¬
parity between test and control islets was not reversed after tissue
culture since both lost insulin at similar rates, and the significant
decrease in the insulin levels of test islets persisted throughout
the 24-hour period (p < 0.02), as shown in Fig. 22.
Ultrastructure of islets
The ultrastructural appearance of islets isolated from pilocarpine
















Figure 22 Insulin content of isolated islets from normal and
pilocarpine-pretreated rats, at isolation and after culture for up to
24 hours. Results are expressed as Mean ± SEM of the number of
observations shown. * and ** indicate significant difference (p < 0.05
and <0.025) between insulin content of islets from control and pilo¬






Figure 23 (x7000 magnification)
Electron micrograph of B cells from an islet isolated from the pancreas
of a rat which had been pretreated with pilocarpine (40 mg/kg) 1 -11
hours before sacrifice, as described in the text.
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Transplantation of islets
The blood glucose concentrations of recipient rats before and
after transplantation of islets from pilocarpine pretreated donors
are shown in Fig. 24. In six successive experiments the streptzotocin-
induced diabetes was effectively reversed within two weeks of trans¬
plantation, as judged by random blood glucose estimations of less than
10 mmol/1, the absence of glycosuria and urine volumes of less than
10 ml/24 hours. These six animals have remained normoglycaemic for
at least 5 months. No amelioration of diabetes has been observed in
three control diabetic animals which did not undergo transplantation.
One of these animals has developed bilateral corneal cataracts, a
character!stic complication of long-standing diabetes, shown in Fig. 25b,
and compared with the appearance of a non-diabetic rat in Fig. 25a.
Discussion
The number of islets obtained from control donors was comparable
to that reported by Pipeleers et at. (1976), and the results here con¬
firmed the findings of Kuo et al. (1973) that pilocarpine was clearly
useful for enhancing islet yield from rat pancreas. Nevertheless, the
reduced insulin content of islets from pretreated rats indicated that
they were not comparable to normal islets. In an attempt to restore
the depleted insulin content of islets isolated from pilocarpine pre¬
treated rats to normal levels, the islets were maintained in tissue
culture for 24 hours. The insulin content of control islets fell during
this period, as described by other workers (Andersson, 1974J,but the
comparative reduction of insulin stores produced by pilocarpine pre-
























—r—ii I I—l i i » |
1st 3rd 5th 7th 9th 11th
WEEKS AFTER TRANSPLANT
Figure 24 Random blood glucose concentrations of rats before and after
transplantation of 1000+ islets from pilocarpine-pre-treated rats via
the portal vein. Results shown are Mean ± SEM for 6 consecutive
transplants.
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rigure 25b Diabetic rat which has developed bilateral corneal
cataracts.
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islets from pilocarpine pretreated animals were not considered
suitable for the investigation of islet function and metabolism in
short-term 'in vitro1 studies, even after a 'recovery1 period of
24 hours in tissue culture.
However, pilocarpine pretreatment of rats undoubtedly enhanced
islet yield from the pancreas. In view of the normal ultrastructure
of B cells from islets of pilocarpine pretreated rat pancreas, it
seemed possible that the method could have an application in experi¬
ments where a large quantity of islets and their long-term survival
were the important criteria - islet transplantation provides one
such application.
Transplantation of isolated rat islets from adult animals to
diabetic recipients has become a valuable and widely-used model for
the investigation of transplantation of the endocrine pancreas. The
reversal of streptozotocin-induced diabetes in rats by syngeneic
intraperitoneal transplantation of collagenase isolated islets was
first reported by Ballinger and Lacy (1972), but it was clear that the
amount of donor islet tissue used was an important factor in the
degree of amelioration of diabetes (Ziegler, 1974). If the number of
viable transplanted islets was below a minimal level, the experimental
animals reverted to a diabetic state, probably through exhaustion of
the B cells by overstimulation (Ziegler, 1974). Successful trans¬
plantation relies on the long-term viability of islets, and an initial
disturbance of B cell response to hyperglycaemia may be unimportant.
Therefore we investigated the possibility of using islets from pilo¬
carpine pretreated rats for transplantation.
Preliminary studies, and the available literature (Schulak,
1978) indicated that intraportal transplantation of 1000 or more islets
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from untreated rats was sufficient to consistently reverse
streptozotocin-induced diabetes in syngeneic recipients. . An identical
procedure was adopted for transplantation of islets from pilocarpine
pretreated donors. It was clear that such islets could effectively
reverse the diabetic state in the recipients, and pilocarpine pre-
treatment was evidently useful in experimental work on transplantation.
Conclusion
Pretreatment of rats with pilocarpine effectively enhanced the
subsequent yield of isolated islets, but these islets were judged to
be unsuitable for use in metabolic studies in view of the observed
depletion of insulin stores. Nevertheless, they evidently retain
their capacity to secrete insulin, and pilocarpine pretreatme'nt pro¬
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